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TITLE OF THE ABSTRACT: The Determination of Incidence and Risk Factors for Deep Venous 
Thrombosis in the Medical Intensive Care Unit 
DEPARTMENT: General Medicine 
NAME OF THE CANDIDATE: Adhiti.K. 
DEGREE AND SUBJECT: MD, General Medicine 
NAME OF THE GUIDE: Dr. Thambu David, Professor and Head, Medicine – II, Christian Medical 
College, Vellore. 
OBJECTIVES: This study was aimed at determining the incidence of deep venous thrombosis (DVT) 
in the medical intensive care unit (while on thromboprophylaxis), and describing the risk factors 
associated with the same.  
METHODS: All patients getting admitted to the medical intensive care unit (MICU) underwent  
screening with compression ultrasound, at four points on each side (jugular, axillary, femoral and 
popliteal), after informed consent. This was done on days 1, 3 and 7 of admission into the MICU. All 
patients were on thromboprophylaxis (pharmacological/mechanical) as per the existing protocol. The 
primary outcome was the incidence of DVT (as defined by those occurring on days 3 or 7). The 
secondary outcomes were death and duration of hospitalization. The risk factors studied included those 
related to the pre-existing comorbidities, current illness and interventions in the MICU. 
RESULTS: This study was done in a tertiary care hospital, on 219 patients who were admitted in the 
MICU, between June 2013 and April 2014. The incidence of DVT in the MICU was 17.2%, 
(n=35/203, 16 patients had DVT on day 1, and hence excluded). Two thirds were catheter associated 
DVTs (23/35). There was no significant difference in the mortality (9/35 vs. 40/168, p=0.81), although 
the median duration of hospitalization at discharge (20.5 vs. 10.5 days) was longer for the DVT group. 
Central venous catheters (RR=15.97, p = 0.01) emerged as the sole risk factor independently 
associated with the development of DVT in the MICU. 
CONCLUSION: There needs to be a low threshold for suspicion of DVT in the MICU. 
Administration of standard thromboprophylaxis and periodic ultrasound Doppler screening for the 
same helps in improving outcomes. Appropriate use and timely removal of central venous catheters is 
important to reduce the occurrence of DVT.  
Keywords: deep venous thrombosis, medical intensive care unit, central venous catheters 
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INTRODUCTION	  
	  
 Deep venous thrombosis (DVT) is frequent among critically ill patients, the risk arising from 
immobilization, co-morbidities and interventions in the form of mechanical ventilation and central 
venous catheters. The incidence of DVT in the medical intensive care unit (MICU) was reported to be 
around 30% before thromboprophylaxis became part of routine care(1,2). 30-50% of untreated DVTs 
develop into pulmonary embolism (which is fatal in 10-12% of hospitalized cases) and when treated, 
the numbers significantly reduce to 2-4%.(3) Asymptomatic DVTs and upper limb thrombi likewise, 
which were initially thought to be of no relevance, have now been found to play a  role in decreasing 
the long term survival of the patients.(4)(5,6)  
Current protocols incorporate DVT prophylaxis as a part of standard practice for ICU patients. It 
is still unclear, if these measures have significantly impacted the development of deep venous 
thrombosis, though it has been shown in a Canadian study that increased adherence to 
thromboprophylaxis by 10%, results in 16 fewer deep venous thrombotic events and one fewer 
pulmonary embolus (7).  
Further, there are limited studies on venous thrombosis in critically ill hospitalized medical 
patients in India.(8,9) Although it has been the perception that Indian patients may be at a lower risk of 
venous thrombosis, in view of a lower frequency of mutations predisposing to thrombosis; recent 
multinational worldwide trials have suggested that Indian patients are almost at the same level of risk 
as that of the western population, and that thromboprophylaxis is largely underutilized in India.(11) . 
This study attempts to fill these gaps in knowledge by assessing the incidence of deep venous 
thrombosis in the medical intensive care unit and determining the risk factors associated with 
development of the same in critically ill hospitalized medical patients. 
12	  
	  
AIMS	  AND	  OBJECTIVES	  
	  
AIM	  OF	  THE	  STUDY	  
	  
To study the occurrence of deep venous thrombosis in hospitalized critically ill 
medical patients in Christian Medical College, Vellore and to assess the factors 
associated with its development. 
OBJECTIVES	  
	  
1.To determine the incidence of deep venous thrombosis in the medical intensive care 
unit, Christian Medical College, Vellore. 
2.To assess the risk factors playing a role in the development of deep venous 
thrombosis in the medical intensive care unit, Christian Medical College, Vellore. 
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LITERATURE	  REVIEW	  
 
DEFINITION	  
 
“Thrombus” is defined as a stationary blood clot lodged in the blood vessel, frequently causing 
vascular obstruction.(10) “Deep venous thrombosis” refers to a blood clot in the major veins of the 
body, especially in those of the pelvis or lower limbs. Pulmonary embolism is a fatal complication 
arising from the disruption of the clot and its travel through the venous circulation, to get lodged in the 
pulmonary vasculature.(11) Deep venous thrombosis also results in post thrombotic or post phlebitic 
syndrome, as a long term sequele. Venous thromboembolism is a term that includes both, deep venous 
thrombosis and pulmonary embolism, which in itself, is a sequele of the former. (12) 
HISTORY	  
 
The first well documented case of DVT dates back to the Middle Ages (1271), where the 
presentation was characterized by unilateral ankle edema. Thereafter, the number of cases increased 
steadily, especially being reported among the pregnant and postpartum women.(13) DVT was thus, 
discovered in the 13th century(14), primarily as a phenomenon occurring in the pregnant women, who 
were therefore encouraged to breastfeed to prevent the same. It was, for this reason, also called “milk 
leg”.(15)  In 1856, Rudolph Virchow proposed the Virchow triad to explain the pathogenesis. Nearly 
a century later, the pharmacological therapy for the same was introduced. Diagnostic modalities for 
DVT were also developed during the twentieth century, with the ultrasound Doppler, a relatively 
simple and less time consuming technique, deserving a worthy note of mention for its role in 
diagnosis of the same.(16)  
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GLOBAL	  EPIDEMIOLOGY	  –	  DVT	  in	  the	  World	  
 
The annual incidence of DVT is estimated at 1-3 per 1000 adult population.(17) In the United 
States of America, 3,00,000-6,00,000 patients suffer from DVT every year. Half of these patients 
develop post thrombotic syndrome and one third develop recurrence of venous thromboembolism over 
the subsequent 10 years.(18)  
Venous thromboembolism related deaths are estimated to occur at 1,00,000-3,00,000 per year. 
Pulmonary embolism was declared by the US Surgeon General as the most common preventable cause 
of death among hospitalized patients in the United States.(12) Pulmonary embolism attributes to 
60,000 – 1,00,000 deaths in the United States every year. One quarter of patients with pulmonary 
embolism present with sudden death and 10-30% experience death within the first month of 
diagnosis.(18) In Europe, 3,70,000 deaths occur annually due to pulmonary embolism.(12)  
One study conducted at Boston, similar to our proposed research scheme, at a time when 
thromboprophylaxis was not part of routine care in the intensive care setting, showed that the 
incidence of DVT in the MICU was as high as 33%. Though this study was done nearly two decades 
ago, it is unique in two aspects – 1) it was a prospective study, as compared to many other studies 
which were done on DVT, at the same time, all of which were retrospective and 2) it looked at upper 
extremity, lower extremity and central venous catheter related thrombosis, unlike most other studies 
which looked only at proximal lower extremity thrombosis. (1) 
The ENDORSE study, aimed at estimating the proportion of hospitalized patients at risk for deep 
venous thrombosis and the access to and adequacy of prophylaxis in the same, determined that 36-73% 
of hospitalized patients all over the world, were  at risk of developing deep venous thrombosis; among 
whom 2-84% received prophylaxis. Among the hospitalized medically ill patients, 21-71% of patients 
were at risk of deep venous thrombosis.(19) Therefore, it was seen that although, there was a large 
15	  
	  
proportion of hospitalized patients, who were at risk for development of DVT, thromboprophylaxis 
was still largely underutilized even in the current era. 
INDIAN	  SCENARIO	  –	  DVT	  in	  India	   	  
 
The annual incidence of DVT in India is estimated to be at one percent of adult population above 
the age of forty years and 15-20% among hospitalized patients. One percent of cases with DVT 
develop pulmonary embolism. One out of every two hospitalized patients in India are at high risk for 
developing venous thromboembolism at any point of time.(20)  
A retrospective study done in South India, showed that the incidence of DVT was 17.46 per 
10,000 hospital admissions.(21) Therefore, in contrast to the popular belief earlier, that Indian patients 
were at reduced risk for development of DVT, studies have shown that the risks are similar to that in 
the other parts of the world. The ENDORSE study showed that 45% of hospitalized medically ill 
patients in India are at risk of DVT; among whom, only 22% received thromboprophylaxis.(19) This 
study showed that the need for thromboprophylaxis is largely underestimated in India.  
Indian studies have shown that the incidence of DVT among hospitalized critically ill medical 
patients range from 3% to 13.5%.(9,22) However, there have been no uniform protocols regarding 
thromboprophylaxis in these studies and as a result, the thromboprophylactic measures are inadequate 
and incomplete. There is paucity of data on studies which have been done on standard 
thromboprophylaxis protocols.  
PATHOPHYSIOLOGY	  	  
 
In 1856, Rudolph Virchow attributed thrombus formation to the interplay between the factors of 
the Virchow’s triad, namely endothelial injury, hypercoagulability and alteration in blood flow (stasis 
in veins, and turbulence in arteries).(12) 
16	  
	  
Recent studies have led to the refinement of Virchow’s initial proposed model. Activated 
coagulation is the primary etiological factor in venous thrombosis; while stasis is largely regarded as a 
permissive factor. The concept of venous injury has expanded to include molecular changes occurring 
at the level of the endothelium. The natural history of acute deep venous thrombosis is now thought of, 
largely as a balance between recurrent thrombotic events and processes aimed at restoring the venous 
lumen.(23) 
The thrombus formed in the proximal deep veins of the legs can migrate to the pulmonary 
circulation and get lodged in the pulmonary arteries resulting in the dreaded sequele, pulmonary 
embolism.  Isolated thrombi in the calf veins are smaller and are more commonly involved with 
paradoxical embolism to the systemic circulation, in the presence of septal defects. With increase in 
the use of central venous catheters, upper extremity thrombi have also become fairly common in the 
hospitals of today, the clinical significance of which was hardly known.(12) Recent studies have 
shown that the majority of upper extremity thrombi are catheter associated and resolve spontaneously; 
with the risk of embolization being 2%.(5)  
DVT can be fatal when it leads to pulmonary embolism or can cause delayed complications 
among survivors like chronic thromboembolic pulmonary hypertension and post phlebitic 
syndrome.(12) 
Pulmonary hypertension results from increased vascular resistance distal to the embolus and is 
often distressing as it amounts to a significant degree of breathlessness on exertion.(12) 
Post phlebitic syndrome, also known as chronic venous insufficiency, results from the 
incompetence of the venous valves which occurs secondary to a long standing deep venous thrombus. 
It is disabling, as it results in swelling, pain and ulcers over the legs.(12) 
17	  
	  
PREDISPOSING	  FACTORS (12)   
Co morbidities: 
  Cancer 
  Chronic Obstructive pulmonary disease 
  Hypertension 
  Pregnancy 
  Surgery  
  Trauma 
  Previous venous thromboembolism(24) 
  Hospitalization(25) 
  Neurological diseases with paralysis, e.g.: stroke(25) 
  Thrombophilias 
   Inherited: 
    Factor V Leiden mutation 
    Protein C deficiency 
    Protein S deficiency 
    Antithrombin III deficiency 
   Acquired: 
18	  
	  
    Antiphospholipid antibody syndrome 
  Admission to intensive care units(1) 
  (Risk factors unique to ICU stay are as follows) 
   Central venous catheters(26) 
   Peripherally inserted central venous catheters(27) 
   Mechanical ventilation    
Sedatives 
   Muscle relaxants    
Vasopressors 
   Transfusions  
 Lifestyle: 
  Long haul air travel 
  Smoking 
  Red meat 
 Drugs: 
  Oral contraceptive pills 
  Hormone Replacement Therapy 
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IMPACT	  OF	  DEEP	  VENOUS	  THROMBOSIS	  
 
 DVT is a frequently encountered problem in hospitalized patients.(1,19,25) It contributes to a 
large proportion of hospital acquired mortality (in the form of pulmonary embolism) and morbidity (in 
the form of post phlebitic syndrome and thromboembolism pulmonary hypertension).(12) One 
community based study had shown that the in-hospital case fatality rate of venous thromboembolism 
was 12%, and among those discharged, the long term case fatality rates were 19%, 25%, and 30% at 1, 
2, and 3 years after discharge respectively.(28) It was always thought of as a disease of the western 
population; but recent studies have shown that the risk of deep venous thrombosis among hospitalized 
patients is almost comparable between India and the west.(19)  
HEALTH	  CARE	  COSTS	  OF	  VENOUS	  THROMBOEMBOLISM	  
	  
 Western studies have shown that the development of an in-patient DVT, pulmonary embolism 
or both results in additional costs of $8000, $14,000 and $28,000 over and above the final bills of 
general medical patients.(30) The annual health care costs implicated in hospital acquired DVTs was 
estimated to range between 6.8 and 36 billion US dollars in the United States of America.(31) Studies 
have also shown that the presence of DVT leads to increase in the length of ICU stay and hospital stay, 
thereby, draining the health care resources. (26)  
DEEP	  VENOUS	  THROMBOSIS	  IN	  THE	  MEDICALLY	  ILL	  
	  
 There is an increase in the number of hospitalized medical patients at risk for development of 
DVT, than the surgical patients.(12) Recent studies have shown that the risk for development of DVT 
was slightly and surprisingly higher among medical patients as compared to surgical patients (6.48 vs. 
5.0).(32) Several studies have been done in the western population on DVT in the hospitalized 
critically ill medical patients. Studies done during the last two decades have demonstrated a higher 
20	  
	  
than anticipated prevalence of deep venous thrombosis among these patients.(1,33–35) Most of these 
studies were retrospective in nature; and therefore limited data was available on the unique factors 
playing a role in the development of deep venous thrombosis in the intensive care setting.(26,36)  An 
Indian study has shown that 75% of patients admitted to the general medical wards and intensive care 
units are at high risk for development of DVT.(8) 
DEEP	  VENOUS	  THROMBOSIS	  IN	  THE	  INTENSIVE	  CARE	  SETTING	  
	  
The incidence of DVT amongst  hospitalized medically ill patients in the intensive care setting 
was reported to be as high as 33% in the pre-thromboprophylaxis era.(1) This has come down to 15% 
after initiation of thromboprophylaxis, as reported by most of the recent studies.(33,35,37)  
A Canadian study done amongst critically ill, medical and surgical patients (more than two 
thirds of which were medically ill, non-surgical patients), in the intensive care setting, showed that the 
prevalence of DVT was 5.37%. But the thromboprophylaxis coverage in this study was only 
62.5%.(26)  A recent Chinese study assessed the need for thromboprophylaxis by studying the 
incidence of DVT in the intensive care unit. It was estimated to be 19% in the absence of 
thromboprophylaxis.(33) Another study, based in the intensive care unit, in Beijing, determined the 
incidence of DVT to be 15.1%, with 7.5% having suspected pulmonary embolism, and 1.7% having 
confirmed pulmonary embolism.(35)  A study in Thailand, estimated the incidence of DVT in the 
MICU to be 8.82%, with incomplete thromboprophylaxis coverage.(37)  A retrospective study from 
Iran, determined the incidence and prevalence of proximal lower limb DVTs in the medical and 
surgical intensive care units to be 5.2% and 9.4% respectively.(38)  
It was seen from the above studies that, the incidence of DVT in the intensive care setting is 
highly variable (5-15%), especially in the medically ill patients. This discrepancy can be largely 
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attributed to the absence of standard protocols for thromboprophylaxis in most medical intensive care 
units, as a result of which there is a wide variation in the implementation of the same.   
However, with recent guidelines insisting on implementation of thromboprophylaxis (either 
pharmacological, or mechanical in the event of contraindications for the former) as part of standard 
care in the intensive care setting, there have been a few studies which looked at the occurrence of DVT 
amongst patients on standard thromboprophylaxis.  
A study from Washington, USA, done in the MICU, to determine the presence of DVT in 
patients requiring prolonged mechanical ventilation (>7 days), estimated an incidence of 23.6% 
despite 100% thromboprophylaxis coverage.(39) Another study from Massachusetts, USA, showed 
that the incidence of proximal lower limb DVTs was 12% despite 92% thromboprophylaxis 
coverage.(40) These studies were limited by the small numbers of patients being studied.  
The PROTECT trial was a large multicentric trial done on patients in the intensive care units. 
This was a randomized controlled trial done to compare the efficacy of unfractionated heparin vs. low 
molecular weight heparin (dalteparin was chosen as it was safe in renal dysfunction) in preventing 
proximal lower limb DVTs. All patients were randomized to receive unfractionated heparin or 
dalteparin as part of their thromboprophylaxis and the median duration of receiving 
thromboprophylaxis was for a week. It was seen in this study that, despite 100% thromboprophylaxis 
coverage, the incidence of proximal lower limb DVT was overall 5.47% (5.1% in the dalteparin group 
vs. 5.8% in the heparin group), with the incidence of pulmonary embolism being 1.79%. 88.7% of the 
DVTs and 70% of the pulmonary emboli were detected during the ICU stay, implying that the largest 
risk of development of DVT in hospitalized patients was within the intensive care setting.(41)  
As most of the afore mentioned studies have only focused on the presence of proximal lower 
limb DVTs, these figures could largely underestimate the total venous events (inclusive of the upper 
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extremity and axial venous thrombosis (like splanchnic and cerebral vein thrombosis)) occurring in the 
intensive care setting, which could also influence the mortality and morbidity of these patients.  
Upper extremity thrombi have been reported only by a few DVT studies. One of the earlier 
studies, done in the pre-thromboprophylaxis era, determined the incidence of upper extremity DVTs in 
the MICU to be 5%.(1) The PROTECT trial showed that the incidence of non leg DVTs, while on 
thromboprophylaxis, was 2.2%, with 94.5% of them originating in the upper limbs.(42)  
Deep venous thrombosis in the Indian subcontinent is a topic where recent exploration has 
begun. Several studies have been done on DVT in hospitalized surgical patients in India; in contrast to 
the paucity of studies done on medical patients. A study has shown the incidence of DVT among 
hospitalized medical patients (in the general medical wards and intensive care units) to be around 3% 
in India. These patients were not on standard thromboprophylaxis.(9) Another study which looked at 
the thromboprophylaxis and patients at risk for DVT amongst those admitted in the general medical 
wards, showed that the initiation of thromboprophylaxis within the first few days of admission had 
been seen only in 12.5% of patients. Further, 72% of patients who required hospitalization beyond two 
weeks were found to be at high risk for DVT.(8) Thus, thromboprophylaxis is largely underutilized in 
India.  There have not been any studies in India which have attempted to explore the frequency of 
DVT, in hospitalized critically ill medical patients on thromboprophylaxis, and the risk factors unique 
to a medical intensive care setting. 
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FACTORS	  ASSOCIATED	  WITH	  DEVELOPMENT	  OF	  DVT	  IN	  THE	  MICU	  
 
 The risk factors studied for deep venous thrombosis include: 
Host factors: elderly age group, female gender, obesity(37,40) 
Co-morbidities: Malignancy, surgery, trauma, pregnancy, post-partum, hospitalization, 
previous venous thromboembolic events, hospitalization, thrombophilias, pacemakers, 
varicose veins, air-travel, renal failure, chronic obstructive pulmonary disease, 
congestive cardiac failure, neurological diseases.(25,40,43) 
Addictions: Smoking, Alcohol(12) 
Drugs: hormone replacement therapy, oral contraceptive pills(12) 
ICU related: central venous catheters, peripherally inserted central venous catheters, 
mechanical ventilation, use of sedatives, muscle relaxants & vasopressors, dialysis and 
transfusions(25,26,35) 
DIAGNOSIS	  OF	  DEEP	  VENOUS	  THROMBOSIS	  IN	  THE	  CRITICALLY	  ILL	  
 
 The modalities for diagnosing DVT have also evolved from complex, time-consuming 
techniques like phlebography, impedance plethysmography, and magnetic resonance venography, to 
simpler, bedside, cost effective tools like the Doppler and compression ultrasonography.(43) Several 
studies have shown that the compression ultrasound is a highly sensitive and specific tool for bedside 
diagnosis of DVT by criticare physicians.(44–46) It is not only time-saving, but also cost effective, 
easily accessible, and a simpler technique to master. Compression ultrasound, when compared to the 
duplex ultrasound, has a sensitivity of 88.9%, specificity of 75.9% and a negative predictive value of 
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95.7%.(47) The sensitivity and specificity of compression ultrasound in the hands of criticare 
physicians as a screening tool for DVT has been estimated at 100% and 99% respectively.(45) 
DEEP	  VENOUS	  THROMBOSIS	  PROPHYLAXIS	  	  	  
 
Studies in surgical patients had shown that thromboprophylaxis was effective against the 
development of DVT. A study done in a neurosurgical intensive care unit, showed that the rate of 
occurrence of DVT came down from 16% to 9% by institution of pharmacological 
thromboprophylaxis, with a relative risk reduction of 43%.(34) Studies amongst medically ill patients, 
have however, shown an incidence of 15-30% of DVT despite the prophylaxis,(1,2,35) which led to 
questions being raised on the rate of implementation, adherence, cost effectiveness and adequacy of 
thromboprophylaxis.(1,1,7,19,26) Factors associated with institutionalization independently account 
for more than half the cases of DVT in the community, and this has also led to a greater need for 
emphasis on thromboprophylaxis.(49) All of this,  has paved way to the ACCP guidelines for 
thromboprophylaxis. The recent ACCP guidelines (2012) state that all critically ill patients are to be 
considered at high risk for DVT, and hence to be started on thromboprophylaxis.(50) 
A	   NOTE	   ON	   THE	   2012	   ACCP	   GUIDELINES	   FOR	   THROMBOPROPHYLAXIS	   IN	  
MEDICAL	  PATIENTS 
 
1) Low risk patients – No need for prophylaxis 
2) High risk patients (including all critically ill patients)  
a. Without bleeding or its risk – pharmacological prophylaxis with unfractionated heparin, 
low molecular weight heparin or fondaparinaux 
b. With bleeding or high risk of it – mechanical prophylaxis with intermittent pneumatic 
compression or graduated compression stockings (as the risk for bleeding decreases, the 
patient can be switched to pharmacological prophylaxis) 
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3) Incidental thrombophilia  
a. With history of previous venous thromboembolism – thromboprophylaxis is essential 
(for lifelong) 
b. Without history of previous venous thromboembolism – no need for prophylaxis 
4) Out patients with malignancy  
a. With other risk factors for venous thromboembolism – Daily thromboprophylaxis  
b. Without other risk factors for venous thromboembolism – No need for prophylaxis 
5) High risk patients on long haul flights – walking, calf muscle exercises, compression 
stockings.(50)  
Therefore, by the turn of the last decade, deep venous thrombosis was largely considered a 
preventable disease, widely prevalent among hospitalized patients, contributing to a large share of 
mortality and morbidity worldwide and in India, and the need for its prophylaxis was grossly 
underestimated.(19) 
RELEVANCE	  OF	  THE	  RESEARCH	  TOPIC	  
 
 Deep venous thrombosis is a major public health problem in the global and Indian scenarios. 
The proportion attributed to hospitalization is largely preventable. A large number of studies in the 
western population have described the disease frequency and the associated risk factors and have 
thereby resulted in the formation of guidelines for diagnosis, prophylaxis and management of the 
same, which are also being practiced in India. 
There has been a steady increase in the number of studies on deep venous thrombosis in the 
Asian population, over the last decade, with the major contributions coming from China and Thailand. 
(33,35,37) Indian studies on deep venous thrombosis are limited. (8,9) 
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There are only a few studies which have looked at both, upper and lower extremity thrombi(1); 
as most studies generally tend to focus on the lower extremity thrombi because of their implications in 
the form of pulmonary embolism and therefore mortality. Recent studies have shown that upper 
extremity thrombi also contribute to pulmonary embolism (in lower frequency) and reduced overall 
long term survival.(5,6) In view of the increasing trend in the use of central venous catheters and 
peripherally inserted central venous catheters and therefore, a higher than anticipated incidence of 
upper limb thromboses, it was decided to specifically look for upper extremity and lower extremity 
thromboses during every screening in the study, so as to be able to unify the pathophysiological factors 
playing a role in the development of deep venous thrombosis, irrespective of the site. 
 Recent multinational worldwide trials have shown that the Indian hospitalized patients are 
almost at the same level of risk as that of the western population, and thromboprophylaxis is largely 
underutilized in India.(19) This prompted us to do research on this sparsely explored field.  
The incidence and risk factors of deep venous thrombosis in hospitalized critically ill medical 
patients in India have not been assessed in the past. This study is aimed at determining the disease 
frequency in a high risk population (hospitalized critically ill medical patients in the intensive care 
unit) in a standard protocolized environment (on thromboprophylaxis), which will in turn reflect on the 
need and adequacy of thromboprophylaxis in India. The study also hopes to describe risk factors 
unique to the Indian population in the intensive care setting, for development of deep venous 
thrombosis; assessment and evaluation of which might modify the guidelines for its management, in 
order that they are more endogenous and appropriate to the Indian population. It might also help us to 
better understand the role of various factors in the pathogenesis of DVT. 
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METHODS	  
	  
SETTING	  
	  
This study was done from June 2013 to April 2014 in the Department of General Medicine, 
Christian Medical College, Vellore, at the medical intensive care unit and high dependency unit. 
Christian Medical College, Vellore, is a 2695 bedded multispeciality hospital and medical 
college which caters to 1.9 million out-patients and 1.2 lakh in-patients annually and 5500 out-
patients, 2500 in-patients, 75 surgical procedures, 22 clinics and 30 births on a daily basis. 
The Medical Intensive Care Department functions as a 24 bedded complex that includes  the  
Medical Intensive Care Unit and the Medical High Dependency Unit, with 12 beds in each. There are 
1500-1600 admissions on a yearly basis and 100-120 admissions on a monthly basis, with more than 
two thirds of the admissions requiring mechanical ventilation, and around half the patients requiring 
more than one week of stay in this setting. Around half of these patients belong to the department of 
medicine, while the remaining stream of patients stem from various medical superspecialities like 
hematology, rheumatology, gastroenterology, neurology, nephrology, endocrinology and cardiology. 
The mortality rate in the medical intensive care unit and high dependency unit, is around 25%. 
STUDY	  DESIGN	  
	  
 A prospective observational cohort study design was adopted to determine the incidence and 
risk factors for the development of deep venous thrombosis in the Medical ICU.  
The primary objective of the study was to determine the incidence of deep venous thrombosis 
in the hospitalized, critically ill medical patients, despite  adequate thromboprophylaxis.  Therefore, 
a prospective study design, was considered appropriate to assess the primary objective.  
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This study was done entirely in patients belonging to the unit of Medicine, getting admitted 
to the Medical ICU. This gave us the opportunity of studying an exclusive cohort of patients in a 
standard protocolized environment. The secondary objective was to assess the risk factors for 
development of DVT in this group of patients. Hence a prospective cohort study was considered 
ideal for determination of incidence and risk factors for deep venous thrombosis in this cohort of 
hospitalized patients in the medical intensive care setting. 
PATIENTS	  
	  
INCLUSION	  CRITERIA	  	  
	  
All patients belonging to general medicine, above the age of 16 yrs, admitted in the 
medical intensive care unit and the medical high dependency unit between June 2013 and 
April 2014 were included in the study. 
EXCLUSION	  CRITERIA	  
	  
1) Patient/caregiver refusing consent for entering the study 
2) Admission diagnosis of Deep venous thrombosis / Pulmonary embolism 
3) Patient already on therapeutic anticoagulation, e.g.: prosthetic heart valves 
4) Readmission to MICU/MHDU within a single hospital stay 
 Patients who had died or who had been discharged from the hospital within 48hrs of 
admission into the medical intensive care unit or high dependency unit, were also excluded 
from the study, post inclusion. Patients who got transferred to the wards before they were  
screened with their day 3 & 7 ultrasound Dopplers, were followed up and screened in the 
ward on the respective days. Those who had got discharged before their day 7 ultrasound, 
were considered as lost to follow up for the last follow up scan.  
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PROTOCOL	  IMPLEMENTATION	  
	  
 A protocol for thromboprophylaxis (Appendix 1) has been in place in our medical 
intensive care unit and medical high dependency unit. The protocol was created by Dr.George John, 
Professor and Head, Medical Intensive Care Unit and is being followed since 3-4 years. 
ULTRASOUND	  TRAINING	  OF	  THE	  INVESTIGATOR	  
	  
 The principal investigator (self) was trained in compression ultrasound for detection of deep 
venous thrombosis by Dr. Kishore Pichamuthu, Associate Professor, Medical Intensive Care Unit, 
over a period of 2 weeks. Dr. Kishore was trained in critical care sonology in Westmead Hospital 
ICU, Sydney. He has designed a website on critical care echocardiography and ultrasound 
(www.criticalecho.com). He is also involved in the training of students and faculties in ICU 
sonology in CMC hospital, Vellore and conducts annual hands-on workshop on ICU sonology.  
ULTRASOUND	  TECHNIQUES	  USED	  
	  
Ultrasonography is the current first-line imaging examination for deep venous thrombosis 
(DVT) because of its relative ease of use, absence of irradiation or contrast material. Previously 
quoted studies have shown superior sensitivity and specificity for the compression ultrasonography 
for the diagnosis of DVT, even in the hands of emergency and criticare physicians. 
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ULTRASOUND	  MACHINE	  AND	  THE	  VASCULAR	  PROBE	  
	  
M-Turbo Ultrasound machine (Sonosite) [dynamic range up to 165 dB] is the bedside 
ultrasound machine that was used for the study. The high frequency catheter probe (gives high 
resolution of images near the body surface and hence), preferred for vascular imaging, was used for 
the diagnosis of DVT in this study. It resembles a tiny leg and foot, with the transducer being present 
in the foot region. It has a frequency range of 7-12 MHz and has colour flow imaging and pulse wave 
Doppler. 
 
 
 
 
 
 
 
 
Ultrasound Machine (to the left) 
Vascular probe (below) 
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POSITIONING	  OF	  THE	  PATIENT	  AND	  THE	  PROBE	  
	  
 For the assessment of lower limb DVT, the patient is supine with the legs exposed up to the 
inguinal ligament. Bedside ultrasonography for lower limb deep vein thrombosis (DVT) is 
performed at 2 principal sites, one on each side – the femoral and the popliteal. Ideally, 30-40 
degrees of reverse Trendelenburg facilitates the examination by increasing venous distension. The 
probe is held with its long axis (of the foot – transducer region) perpendicular to the axis of the 
vessel being studied.  
 When examining the femoral vein, the patient’s hip is externally rotated and flexed for better 
and easy visualization. The probe is placed at the mid inguinal point, just below the inguinal 
ligament. The vein is located medial to the artery at this point.  When examining the popliteal vein, 
the popliteal fossa on the posteromedial aspect of the knee is exposed by bending the knee and 
externally rotating the hip. At the popliteal fossa, the probe is placed and the vein lies superficial to 
the artery here.  
 The assessment of upper limb DVT is also done in the supine position, in 2 principal sites, 
namely, the jugular and the axillary. For this, the Trendelenburg position facilitates better 
visualization of the upper limb veins due to venous distension. When examining the jugular vein, the 
patient’s head is turned towards the opposite side and the probe is placed along the anterior border of 
the sternocleidomastoid at the junction of upper two-thirds and lower one-third. The vein is usually 
superficial to the artery here.  When examining the axillary vein, the patient’s arm is extended and 
abducted and the probe is placed at the axilla towards the apex and manoeuvred until visualization of 
the axillary vessels is made. The position of these vessels is highly variable.  
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Positioning	  for	  Axillary	  vein	  screening	  Positioning	  for	  Jugular	  vein	  screening	  
Positioning	  for	  Popliteal	  vein	  screening	  
Positioning	  for	  Femoral	  vein	  screening	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IDENTIFICATION	  OF	  THE	  VEIN	  FROM	  THE	  ARTERY	  	  
	  
 The vein is differentiated from the artery based on 5 sonological attributes: 
Sonological Characteristics Vein Artery 
Shape Ovoid Round 
Pulsatility Absent Present 
Compressibility Present-Walls meet each other Absent-Stays open 
Colour flow imaging* Continuous undulating flow Intermittent pulsatile flow 
Pulse wave Doppler Steady gradually changing flow Accelerating pulsatile flow 
*In colour flow imaging, identification of the artery and vein merely based on the colours red 
and blue, respectively is not advisable, as the colours can be altered by changing the direction of 
angulation of the probe.  
 
DETERMINATION	  OF	  DVT	  
	  
 The following techniques have been described for the determination of DVT, although 
only lack of compressibility and direct visualization of the thrombus was used in DVT diagnosis 
in our study. 
COMPRESSIBILITY	  
	  
After identification of the vein, pressure is applied vertically downward, 
on the transducer, without changing the position of the probe, with the vein being visualized 
at the centre of the image window. The pressure is applied until the vein collapses 
completely. The artery is generally more resistant to deformation and hence, does not 
collapse.  
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In case of a patent vein with normal flow, the lumen collapses completely 
and the walls touch each other; while the artery beside, is usually still open and pulsatile. 
Subsequently, the pressure on the transducer is relaxed and the vein is allowed to resume to 
its normal shape. The amount of pressure required to collapse a vein will vary from patient 
to patient, and with experience, it is easy to ascertain whether adequate pressure has been 
applied.  
Compressibility indicates lack of thrombus in the vein at that particular 
region. Ideally, this needs to be done along the entire length of the vein. As this is 
cumbersome and time-consuming, there have been studies which had looked at the utility of 
compression ultrasound at a few points along the course of the vein. Studies have showed 
good sensitivity and specificity (100% and 99% respectively) for the 2 point compression 
ultrasound (at common femoral and popliteal) in the hands of emergency physicians in 
diagnosis of DVT. In our study, only this technique was applied at eight points (bilateral 
jugular, axillary, femoral and popliteal) to detect the presence of a thrombus.  
Non compressibility of the vein, even at pressures where the artery starts 
to deform, is indicative of a thrombus. Non compressibility must be interpreted with caution 
because downward pressure at the wrong angle or down the wrong vector can greatly 
decrease the actual pressure felt by the vein and can make it appear non compressible. 
	  
	  
	  
	  
	  
Compressibility	  of	  the	  Femoral	  Vein	   Non	  compressible	  –	  thrombus	  visualized	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PHASICITY	  
	  
                After visualizing the vein and positioning it at the centre of the image 
window, the probe is angulated downwards and the curser of the pressure wave Doppler is 
placed at the centre of the venous lumen. In the Doppler mode, a pressure wave tracing is 
obtained, which shows cardiac and respiratory variations. The respiratory variations are 
more pronounced.  
In spontaneously breathing patients, there is an increased flow during 
inspiration, while the reverse occurs in mechanically ventilated patients. Absence of such 
variation usually signifies proximal thrombosis (between the point being tested and the 
inferior vena cava). This technique was not applied in our study.  
AUGMENTATION	  
	  
The pulse wave Doppler or the colour flow imaging can be used to assess 
augmentation. After visualization of the vein and activation of the pulse wave Doppler 
tracing, the calf muscles are gently squeezed and this results in surge of blood flowing 
through the vein. This causes peaking of the tracing in a normal patent vein. If colour flow 
imaging is activated, it causes an increased flow as visualized by a splurge of colours on the 
imaging. Absence of this response indicates presence of thrombus between the point being 
studied and the calf. This technique was also not used in our study. 
 
	  
	  
	  
Phasicity	   Augmentation	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DIRECT	  VISUALIZATION	  OF	  THROMBUS	  
	  
In a few cases, the thrombus can be visualized as a slightly echogenic 
mass inside the vein lumen. It may be sessile, fixed to the wall or be floating in the flow, 
tethered at one point to the wall. A chronic organized thrombus appears more echogenic and 
is firmly attached to the wall. The degree to which the lumen is obstructed is variable. 
 
 All the aforementioned techniques have been traditionally described for assessment of 
lower limb DVT. In our study, we utilized the principles of compressibility and direct thrombus 
visualization for making a diagnosis of DVT. In the event of absent compressibility, the 
presence of a thrombus was further confirmed with phasicity and augmentation. These 
techniques were used for detection of upper limb and lower limb DVT at four points, where 
compressibility was assessed (jugular, axillary, femoral and popliteal). In the event of direct 
thrombus visualization, compressibility was not done for fear of proximal embolization.  
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SAMPLE	  SIZE	  CALCULATION	  
	  
The sample size was estimated to be 196 with the presumed incidence of deep venous 
thrombosis being 15% (35) amongst patients admitted in the medical intensive care unit. 
Sample size was calculated using this incidence of 15%, confidence intervals of 95% and 
margin of error being 5%. 
Sample size was calculated by the formula     Z(1-alpha)*Z(1-alpha)*P*Q 
            D*D 
 Where Z (1-alpha) is the confidence interval (1.96) 
                       P is the prevalence (15%) 
                       Q is [1-P] (85%) 
                       D is the precision (5%) 
 
Sensitivity table was drawn for an expected incidence of 15%. 
Prevalence (P) 15 15 15 
Alpha 0.05 0.05 0.05 
Z(1-alpha) 1.96 1.96 1.96 
Precision 5 4 3 
Calculated sample size 196* 306 544 
 
 
It was seen from the sensitivity table that, for a higher precision, a larger sample size 
was required for the same prevalence and confidence intervals. For feasibility constraints, it 
was decided to work on the sample size calculated using 5% precision (n=196).  
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Sample size was also calculated for risk factor analysis by considering two important 
risk factors associated with deep venous thrombosis in the intensive care setting – namely 
mechanical ventilation and central venous catheters(25) – to ensure adequacy of the above 
calculated sample size for the risk factor analysis. 
 
 
Mechanical 
Ventilation 
Central Venous 
Catheters 
Proportion of disease among unexposed (40) 0.42 0.03 
Relative Risk  (25) 1.5 5 
Proportion of disease among exposed 0.63 0.15 
Power (1- beta) % 80 80 
Alpha error (%) 5 5 
1 or 2 sided  2 2 
Required sample size in each group  88 88 
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RELIABILITY	  EXERCISE	  –	  KAPPA	  VALUE	  FOR	  AGREEMENT	  
	  
 Reliability exercise was done to determine the rate of inter-observer agreement, prior to 
initiation of the study. This was planned using the Cohen’s kappa co-efficient. This was done with 
three observers: principal investigator (self), co-investigator (Dr. Thomas, Assistant Professor, 
Medical Intensive Care Unit) and a radiologist (Dr.Balaji, Assistant Professor, Dept of Radiology).  
Statistician was consulted and it was decided to perform the reliability exercise on 10% of 
the sample size. As the sample size calculated was 200 and as each patient was planned 3 ultrasound 
scans over a week of admission, it was decided to perform 60 scans (200 X 3 = 600 – 10% = 60) for 
the reliability exercise. Ideally, replicating the study design, each of the observers had to study the 
same 20 patients in the MICU, performing 3 scans over 1 week on each of the patients. But for 
feasibility and ease of conducting the reliability exercise, it was instead decided to perform one 
ultrasound each on sixty different patients admitted in the Medical ICU. 
 This study was done over a period of 10 days and six patients were studied per day. The 
study patients were allotted by a consultant in the MICU. Compression ultrasound was done on eight 
points in each of these patients (bilateral jugular, axillary, femoral & popliteal). Each of these 
patients was scanned by all the three observers at different times in the same day and the 
observations were recorded independently. At each of these points, the presence of DVT was 
assessed by each of these observers, based on compressibility and thrombus visualization. As the 
turnover and the mortality rates in the MICU were high, some of the patients who were scanned by 
one observer were missed by the others (primarily due to death or discharge against medical advice). 
Therefore, only 48 patients were finally assessed, as data on the others were incomplete due to the 
aforementioned reason.  
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The data from these 48 patients were analyzed from all the three observers and kappa value 
for agreement was calculated for each of these points assessed and for the overall presence or 
absence of DVT (Table 1). It was seen that the inter-observer agreement was almost perfect at all 
sites other than jugular (fairly good for jugular). The agreement was substantial for the overall 
presence of DVT. The agreement was statistically significant for all parameters. 
 
Kappa’s Inter-observer variation:  
Site (n=48) Kappa value* P value 
Right Jugular 0.64 <0.001 
Left Jugular 0.49 <0.001 
Right Axillary 1.00 <0.001 
Left Axillary 1.00 <0.001 
Right Femoral 1.00 <0.001 
Left Femoral 1.00 <0.001 
Right Popliteal 1.00 <0.001 
Left Popliteal 1.00 <0.001 
Overall presence of DVT 0.77 <0.001 
*Kappa value interpretation: 
<0.40 – poor interobserver agreement 
0.40-0.75 – fairly good interobserver agreement 
>0.75 – excellent inter-observer agreement 
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DATA	  COLLECTION	  
	  
 The protocol was submitted before the initiation of study and was approved by the 
Institutional Review Board and Ethics Committee (No: 8067). Informed consent was obtained from 
all the participants prior to their entry into the study. All the variables of interest were collected 
through a data abstraction form (Appendix 2) which was duly filled by the principal investigator 
(self) on day 1 of admission. The predictor variables related to treatment and outcomes were filled 
by day 7 of admission, at the time of the last follow up scan, just prior to the patient exiting the 
study. All the variables used in the data abstraction form were clearly defined prior to starting the 
study, to avoid discrepancies and ambiguity (Appendix 3).  
Compression ultrasound was done to detect upper and lower extremity and central catheter 
related deep venous thrombosis. This was done by the principal investigator (self) and a co-
investigator on all participants in the study on day 1, day 3, and day 7 of admission in 
*MICU/MHDU. The day 1 ultrasound was planned to pick up patients positive for deep vein 
thrombosis on day 1 of MICU/MHDU admission itself. As we were looking at the incidence of deep 
venous thrombosis in the medical intensive care unit, in the purest sense, it was decided to exclude 
patients who were positive on day 1 from the incidence data. In the literature review, it had been 
seen that the highest risk for development of deep venous thrombosis in an intensive care setting is 
within the first 48 hours and the second highest is within the first week (1); therefore the timing of 
the subsequent ultrasound screenings had been planned on day 3 and day 7, so as to not miss the 
most vulnerable periods for deep vein thrombus development during an ICU stay.  
Compression ultrasound was done at four points – axillary, jugular, femoral and popliteal – 
on each side and at every time. Absence of compressibility or visualization of thrombus was 
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considered to be positive for deep venous thrombosis. These patients were followed up till the time 
of discharge for ICU & hospital outcomes.  
OUTCOMES	  STUDIED	  
	  
PRIMARY	  OUTCOME	  
	  
DVT	   Encountered	   in	   the	   Study: Patients with any one or both of the 
following features on a screening ultrasound on D1/D3/D7 at any site and at 
one or more sites examined were considered to have a DVT 
1) Lack of compressibility on ultrasound 
2) Visualization of thrombus 
Incident	   DVT	   in	   the	   Medical	   ICU: As the term “incidence” refers to the 
occurrence of new events in a particular setting, in the purest sense, the day 1 
DVTs were not considered as incident DVTs. Incident DVTs in the medical 
ICU refers to the development of DVT on day 3 or day 7, as detected by the 
ultrasound screening.  
	   SECONDARY	  OUTCOMES	  
	  
Death	  
	   ICU	   death: Mortality within the MICU/MHDU, before being 
transferred to the wards, was considered as death in the ICU.  
Hospital	   death: Mortality before discharge of the patient from the 
hospital was considered as hospital death. 
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Cause	   specific	   mortality: All the in-hospital deaths were further 
categorized based on the etiology into 3 sub-groups: 
1) Sudden	   death where the cause was uncertain  (pulmonary 
embolism may be considered as one of the differentials) 
2) Confirmed	   pulmonary	   embolism (by imaging – RA/RV 
dilatation on ECHO or CTPA based diagnosis) 
3) Other	  causes due to established causes other than pulmonary 
embolism 
 Discharge  
Patients who had been discharged alive from the hospital or from the 
ICU/HDU itself, in a stable condition, after completion or initiation of 
treatment. 
Discharge	  against	  medical	  advice  
Patients who had been discharged against medical advice from the 
hospital or from the ICU/HDU, before completion of evaluation or 
management. 
Discharge	  diagnosis	  of	  DVT   
Patients who had been discharged with a diagnosis of DVT from the 
hospital, after initiation of oral anti-coagulation.  
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MEASURES	  TO	  REDUCE	  POTENTIAL	  BIAS	  
	  
 Detection bias was anticipated, as the principal investigator and the co investigator 
were physicians (although trained in criticare sonology) and as their findings might differ from those 
of the radiologist. This bias was reduced by performing a reliability exercise before beginning the 
study and after ascertaining good inter-observer variation through calculation of the kappa co-
efficient (0.77). Recall bias was the other bias that was anticipated to occur during the collection of 
the exposure variables (with respect to past history). All attempts were taken to minimize this bias 
by trying to procure evidence in the form documentation, wherever possible, for the history given by 
the participants. 
STATISTICAL	  METHODS	  
	  
Analysis was done using SPSS version 16 (Copyright 2007). Data was entered in EPIDATA 
software with quality control checks such as range and consistency. Data quality was further 
explored using histogram, Box Cox plots and frequency distributions (which was used for 
continuous variables). Categorical variables have been presented as numbers and percentages and 
continuous variables as mean and standard deviation (SD). If the distribution was skewed, besides 
the mean and SD, Median with interquartile range have also been presented. Categorical variables 
were analyzed using Chi square test with Yates’s correction and Proportion test. Continuous 
variables were analyzed using Independent sample t test. Non parametric Mann Whitney U test was 
used when the distribution was skewed. Logistic regression analysis was done to determine the risk 
factors for DVT with log link.  Model assumptions were checked using likelihood residual plots 
against predicted probability. Goodness of fit of the model was assessed using Hosmer Lemeshow 
chi-square statistics. 
45	  
	  
RESULTS	  
	  
INCLUSION	  OF	  PATIENTS	  AND	  BASELINE	  CHARACTERISTICS	  
	  
 There were 259 patients who were screened for eligibility for inclusion into this study, on 
admission into the medical intensive care unit between June 2013 and April 2014 (Figure 1). Ten 
patients were excluded as per protocol as they were found to be admitted with a diagnosis of DVT or 
pulmonary embolism or were already on anticoagulation therapy at the time of admission. An 
additional 30 patients were excluded post hoc due to death or discharge within the initial 48 hours of 
admission into the MICU.  
 There were 219 patients who were finally included into the study. The mean age of this 
group was 45.3 ± 17.5 yrs and there was a slight male predominance (n=121) (Table 1). The mean 
SOFA score at admission was 7.2 ± 4.2.	   Amongst the risk factors being studied, the ones most 
frequently encountered in this group were: prior hospitalization (n=39, 17.8%), smoking (n=34, 
15.5%), and alcohol intake (n=47, 21.5%). Amongst the effect modifiers being studied, treatment 
with vitamin K, aspirin and clopidogrel was seen in 36 (16.4%), 25 (11.4%) and 19 (8.7%) patients 
respectively. Only 10 patients had symptoms suggestive of deep venous thrombosis, in the form of 
swelling (n=5), warmth (n=3), erythema (n=1) and tenderness (n=1). Majority of the patients were 
on mechanical ventilation (n=164, 74.9%) and central venous catheters (n=154, 70.2%). Femoral 
and jugular catheters were almost equally distributed in the group of patients on central venous 
catheters. It was notable that all 219 patients were on thromboprophylaxis during the study. 
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Figure1:STROBE	  Figure–Flow	  of	  patients	  into	  the	  study	  
(Study	  period:	  June	  2013-­‐April	  2014)	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
No.	  of	  patients	  screened	  
for	  eligibility	  	  for	  inclusion	  
in	  the	  study,	  on	  admission	  
into	  Medical	  ICU	  =	  259	   No.	  of	  patients	  excluded	  =	  40	  
On	  oral	  anticoagulation	  therapy	  =	  7	  
	   For	  Atrial	  fibrillation	  =	  6	  
	   For	  prosthetic	  valves	  =	  1	  
Admission	  diagnosis	  of	  Pulmonary	  embolism/DVT	  =	  3	  
Post	  hoc	  exclusion	  =	  30	  
	   Death	  within	  48	  hrs	  (before	  D3	  scan)	  =	  24	  
	   DAMA	  within	  48	  hrs	  (before	  D3	  scan)	  =	  6	  No.	  of	  patients	  included	  in	  
the	  study	  =	  219	  
All	  patients	  underwent	  D1	  scan	  (n=219)	  
All	  patients	  underwent	  D3	  scan	  (n=219)	  
Patients	  who	  underwent	  D7	  scan	  (n=176)	  
Death	  or	  discharge	  before	  their	  
D7	  scan	  =	  43/219	  (19.6%	  )	  
D1	  DVT	  =	  16/219	  =	  7.3%	  
	  
D3	  incident	  DVT	  =	  28/203	  =	  13.8%	  
	  
D7	  incident	  DVT	  =	  7/175	  =	  4%	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Table	  1.a.	  Baseline	  characteristics	  in	  all	  patients	  studied	  -­‐	  at	  admission	  into	  MICU	  
Characteristics	  of	  patients	  
(n=219)	  
Frequency	  
N	  (%)	  
Mean	  Age	  (yrs)	   45.3	  ±	  	  17.5	  	  
Male	  gender	   121	  (55.3)	  
Past	  history	  
	  	  	  	  	  Surgery	  (within	  4	  wks)	  
	  	  	  	  	  Trauma	  (within	  4	  wks)	  
	  	  	  	  	  Hospitalization	  (>3days)	  
	  	  	  	  	  Previous	  DVT	  
	  	  	  	  	  Pulmonary	  embolism	  
	  	  	  	  	  Central	  catheters	  
	  	  	  	  	  Dialysis	  ports	  
	  	  	  	  	  OCP	  intake	  (within	  4	  wks)	  
	  	  	  	  	  HRT	  (within	  4	  wks)	  
	  	  	  	  	  NSAID	  use	  
	  	  	  	  	  Rheumatic	  /	  autoimmune	  disease	  
	  
14	  (6.4)	  
4	  (1.8)	  
39	  (17.8)	  
	  	  	  -­‐-­‐-­‐	  
	  	  	  -­‐-­‐-­‐	  
4	  (1.8)	  
	  	  	  -­‐-­‐-­‐	  
	  	  	  -­‐-­‐-­‐	  
	  	  	  -­‐-­‐-­‐	  
2	  (0.9)	  
15	  (6.8)	  
Present	  history	  	  
	  	  	  	  	  Congestive	  cardiac	  failure	  
	  	  	  	  	  Chronic	  liver	  failure	  
	  	  	  	  	  Chronic	  kidney	  disease	  
	  	  	  	  	  Malignancy	  
	  	  	  	  	  Pregnancy	  
	  	  	  	  	  Post	  partum	  
	  	  	  	  	  Immobilization	  (stroke/paresis)	  
	  	  	  	  	  Pacemaker	  Insertion*	  
	  	  	  	  	  Smoking	  
	  	  	  	  	  Alcohol	  
	  	  	  	  	  Aspirin	  
	  	  	  	  	  Clopidogrel	  
	  	  	  	  	  Vitamin	  K	  supplements	  
	  	  	  	  	  Other	  comorbidities	  
	  
9	  (4.1)	  
7	  (3.2)	  
14	  (6.4)	  
1	  (0.5)	  
	  	  	  -­‐-­‐-­‐	  
7	  (3.2)	  
7	  (3.2)	  	  
4	  (1.8)	  
34	  (15.5)	  
47	  (21.5)	  
25	  (11.4)	  
19	  (8.7)	  
36	  (16.4)	  
104	  (47.5)	  
	  
SOFA	  score	  at	  admission	  to	  ICU	  
	  
	  
7.2	  ±	  4.2	  
Symptoms	  suggestive	  of	  DVT	  
1) Erythema	  
2) Warmth	  
3) Swelling	  
4) Tenderness	  
10	  (4.7)	  
1	  (0.5)	  
3	  (1.4)	  
5	  (2.3)	  
1	  (0.5)	  
	  
*All	  patients	  who	  had	  undergone	  pacemaker	  insertion	  were	  on	  a	  temporary	  pacemaker.	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Table	  1.b.	  Baseline	  characteristics	  (contd.)	  –	  Interventions	  in	  the	  Medical	  ICU	  
Characteristics	  of	  patients	  (n=219)	   Frequency,	  n	  (%)	  
Treatment	  in	  ICU	  
	  	  	  	  	  Central	  Venous	  catheters	  
	  	  	  	  	  	  	  	  	  	  Internal	  Jugular	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Subclavian	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Femoral	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  	  	  	  	  Peripherally	  inserted	  central	  catheters	  
	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  	  	  	  	  Dialysis	  ports	  
	  	  	  	  	  	  	  	  	  	  Jugular	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Femoral	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  	  	  	  	  Mechanical	  ventilation	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  	  	  	  	  Sedatives	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  	  
	  	  	  	  	  Vasopressors	  
	  	  	  	  	  	  	  	  	  	  Dopamine	  
	  	  	  	  	  	  	  	  	  	  Adrenaline	  
	  	  	  	  	  	  	  	  	  	  Noradrenaline	  
	  	  	  	  	  	  	  	  	  	  Dobutamine	  
	  	  	  	  	  	  	  	  	  	  Multiple	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  	  	  	  	  Transfusions	  
	  	  	  	  	  	  	  	  	  	  Packed	  cells	  
	  	  	  	  	  	  	  	  	  	  Whole	  blood	  
	  	  	  	  	  	  	  	  	  	  Platelets	  
	  	  	  	  	  	  	  	  	  	  Cryoprecipitate	  
	  	  	  	  	  	  	  	  	  	  Multiple	  
	  
154	  (70.2)	  
	  	  	  75	  (48.7)	  
	  	  	  	  	  	  71	  (46.1)	  
	  	  	  	  	  	  4	  (2.6)	  
	  	  	  6	  (3.8)	  
	  	  	  	  	  	  5	  (3.2)	  
	  	  	  	  	  	  1	  (0.6)	  
	  	  	  73	  (47.4)	  
	  	  	  	  	  	  66	  (42.9)	  
	  	  	  	  	  	  7	  (4.5)	  
7.1	  ±	  3.1	  	  
3	  (1.4)	  
	  	  	  	  	  2	  (66.7)	  
	  	  	  	  	  1	  (33.3)	  
7.0	  ±	  2.6	  
17	  (7.8)	  
	  	  	  	  	  4	  (23.5)	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  1	  (5.9)	  
	  	  	  	  	  	  	  	  	  	  3	  (17.6)	  
	  	  	  	  	  13	  (76.5)	  
	  	  	  	  	  	  	  	  	  	  6	  (35.3)	  
	  	  	  	  	  	  	  	  	  	  7	  (41.2)	  
8.8	  ±	  4.9	  
164	  (74.9)	  
7.3	  ±	  5.0	  
134	  (61.2)	  
3.7	  ±	  2.6	  
118	  (53.9)	  
	  	  	  	  	  4	  (3.4)	  
	  	  	  	  	  25	  (21.2)	  
	  	  	  	  	  37	  (31.4)	  
	  	  	  	  	  2	  (1.7)	  
	  	  	  	  	  50	  (42.4)	  
4.1	  ±	  2.8	  
29	  (13.2)	  
	  	  	  	  	  9	  (31.0)	  
	  	  	  	  	  1	  (3.8)	  
	  	  	  	  	  4	  (13.8)	  
	  	  	  	  	  3	  (10.3)	  
	  	  	  	  	  12	  (41.4)	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Table	  1.c.	  Baseline	  characteristics	  -­‐	  Thromboprophylaxis	  and	  Bleeding	  parameters	  
Characteristics	  of	  patients	  
(n=219)	  
Frequency	  
n	  (%)	  
	  
Thromboprophylaxis	  
	  	  	  	  	  Pharmacological	  
	  	  	  	  	  	  	  	  	  	  Heparin	  
	  	  	  	  	  	  	  	  	  	  Enoxaparin	  
	  	  	  	  	  	  	  	  	  	  Adequate	  dosage	  
	  	  	  	  	  Mechanical	  
	  	  	  	  	  Both*	  
	  
	  
219	  (100)	  
	  	  	  	  	  122	  (55.7)	  
	  	  	  	  	  	  	  	  	  	  116	  (95.1)	  
	  	  	  	  	  	  	  	  	  	  6	  (4.9)	  
	  	  	  	  	  	  	  	  	  	  122	  (100)	  
	  	  	  	  	  92	  (42.0)	  
	  	  	  	  	  5	  (2.3)	  
	  
Laboratory	  investigations	  
	  	  	  	  	  Mean	  PT	  
	  	  	  	  	  	  	  	  	  	  D1	  (n=189/219;	  86.3%)	  
	  	  	  	  	  	  	  	  	  	  D3	  (n=206/219;	  94.1%)	  
	  	  	  	  	  	  	  	  	  	  D7	  (n=169/219;	  77.2%)	  
	  	  	  	  	  Mean	  INR	  
	  	  	  	  	  	  	  	  	  	  D1	  (n=189/219=86.3%)	  
	  	  	  	  	  	  	  	  	  	  D3	  (n=206/219;	  94.1%)	  
	  	  	  	  	  	  	  	  	  	  D7	  (n=169/219;	  77.2%)	  
	  	  	  	  	  Mean	  APTT	  
	  	  	  	  	  	  	  	  	  	  D1	  (n=187/219;	  85.4%)	  
	  	  	  	  	  	  	  	  	  	  D3	  (n=205/219;	  93.6%)	  
	  	  	  	  	  	  	  	  	  	  D7	  (n=167/219;	  76.2%)	  
	  	  	  	  	  Mean	  platelet	  counts	  
	  	  	  	  	  	  	  	  	  	  D1	  (n=216/219;	  98.6%)	  
	  	  	  	  	  	  	  	  	  	  D3	  (n=218/219;	  99.5%)	  
	  	  	  	  	  	  	  	  	  	  D7	  (n=175/219;	  79.9%)	  
	  
	  
	  
14.7	  ±	  9.0	  
13.8	  ±	  5.0	  
12.6	  ±	  3.7	  
	  
1.3	  ±	  0.8	  
1.3	  ±	  0.5	  
1.1	  ±	  0.3	  
	  
33.7	  ±	  13.7	  
33.3	  ±	  12.7	  
32.6	  ±	  11.4	  
	  
2,12,745	  ±	  1,42,259	  
2,13,720	  ±	  2,33,085	  
1,88,988	  ±	  1,19,562	  
	  
	  
Mean	  duration	  of	  ICU	  stay	  (days)	  
	  
	  
7.2	  ±	  5.3	  
	  
Mean	  duration	  of	  hospitalization	  (days)	  
	  
	  
14.6	  ±	  11.4	  
*All	  patients	  who	  were	  on	  both,	  pharmacological	  &	  mechanical	  prophylaxis	  were	  on	  	  
unfractionated	  heparin	  as	  part	  of	  the	  former.	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PRIMARY	  OUTCOME:	  INCIDENCE	  OF	  DVT	  IN	  MEDICAL	  INTENSIVE	  CARE	  UNIT	  
	  
The day 1 screening ultrasound, done on these 219 patients, picked up 16 patients with 
DVT (7.3%). All of these 219 patients underwent the day 3 follow up scan, which picked up 
an additional 28 patients with DVT amongst the 203 patients at risk (excluding the day 1 
positive patients) (13.8%). Amongst these 219 patients, the day 7 scan was not done in 43 
patients due to death or discharge within a week of ICU admission. Amongst the remaining 
175 patients at risk, 7 patients had newly developed DVT on day 7 of ICU admission (4%). 
The incidence of DVT in our MICU was 17.2% (n=35/203), of which two thirds were catheter 
related (Table 2). It was interesting to note that three fourths of our DVTs were from the lower 
limb (all but one being femoral thrombi) (Table 3, Figures 2,3).  
Table	  2	  –	  Primary	  Outcome	  :	  Incidence	  of	  DVT	  in	  Medical	  ICU	  (while	  on	  
thromboprophylaxis)	  
Primary	  outcome	   Incidence	   95%	  CI	  
	  	  	  	  	  DVT	  at	  admission	  into	  ICU	  (D1)	  
	  	  	  	  	  Incident	  DVT	  (D3+D7)	  
	  	  	  	  	  	  	  	  	  	  Incident	  catheter	  related	  DVT	  
	  	  	  	  	  	  	  	  	  	  Incident	  non	  catheter	  related	  DVT	  
	  	  	  	  	  Total	  DVTs	  encountered	  in	  the	  ICU	  (D1+D3+D7)	  
16/219	  =	  7.3%	  
35/203	  =	  17.2%	  
23/203	  =	  11.3%	  
12/203	  =	  5.9%	  
51/219	  =	  23.2%	  
(3.85,	  10.7)	  
(12.0,	  22.3)	  
(6.9,	  15.6)	  
(2.6,	  9.1)	  
(17.6,	  28.8)	  
Table	  3	  –	  Site	  of	  DVTs	  encountered	  in	  the	  study	  
Site	  
Incident	  DVTs	  
(D3+D7)	  
(n=35)	  
DVTs	  at	  
admission	  (D1)	  
(n=16)	  
Overall	  
(D1+D3+D7)	  
(n=51)	  
Catheter	  
Related	  
Lower	  Limb	  
	  	  	  	  	  Femoral*	  
	  	  	  	  	  Popliteal	  
25	  (71.4%)	  
24	  (68.5%)*	  
1	  (2.9%)	  
14	  (87.5%)	  
14	  (87.5%)	  
-­‐	  
39	  (76.4%)	  
38	  (74.6%)	  
1	  (1.9%)	  
25/39	  (64.1%)	  
25/38	  (65.7%)	  
-­‐	  
Upper	  Limb**	   8	  (22.8%)	   2	  (12.5%)	   10	  (19.6%)	   8/10	  (80%)	  
Multiple	  sites	  	   2	  (5.8%)	   -­‐	   2	  (3.9%)	   -­‐	  
Catheter	  Related	  	   23	  (65.7%)	   10	  (62.5%)	   33	  (64.7%)	   	  
*2/24	  were	  bilateral	  femoral	  DVTs	  
**All	  upper	  limb	  thrombi	  were	  contributed	  by	  jugular	  involvement.	  There	  were	  no	  axillary	  
thromboses	  in	  our	  study.	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Figure	  2	  -­‐	  Site	  of	  Incident	  DVTs	  
Femoral	  	  
Jugular	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Figure	  3	  -­‐	  Site	  of	  D1	  DVTs	  
Femoral	  	   Jugular	  	  
Figure	  2	  –	  Sites	  of	  Incident	  DVTs	  (Day	  3	  +	  Day	  7)	  in	  the	  Medical	  ICU	  (n=35)	  
Figure	  3	  –	  Sites	  of	  Day	  1	  DVTs	  in	  the	  Medical	  ICU	  (n=16)	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NATURAL	  COURSE	  OF	  THE	  DVTS	  ENCOUNTERED	  IN	  THE	  STUDY	  
	  
Day	  1	  DVTs	  	  
	  
Although the patients who had developed DVT on the day of admission into MICU 
were excluded from the calculation of incidence and from the risk factor analysis (as per 
protocol), they were followed up over one week with the day 3 and day 7 follow up scans. It 
was interesting to note that nearly half of them had resolved by 3 days (first follow up scan) 
and three-fourth by 7 days (Table 4, Figure 4).  
 
	  
	  
Table	  4	  –	  Course	  of	  D1	  DVTs	  in	  the	  Medical	  ICU	  	  
D1	  DVTs	  	   Resolution	  by	  D3	   Overall	  resolution	  by	  D7	  
Lower	  Limb	  (n=14)	   6	  (42.9%)	   10	  (71.4%)	  
Upper	  Limb	  (n=2)	   1	  (50%)	   2	  (100%)	  
Catheter	  Related	  (n=10)	   5	  (50%)	   8	  (80%)	  
Overall	  (n=16)	   7	  (43.8%)	   12	  (75%)	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Figure	  4	  -­‐	  Course	  of	  D1	  DVT	  
Overall	  
Lower	  Limb	  
Upper	  Limb	  
Figure	  4	  –	  Course	  of	  the	  day	  1	  DVTs	  (n=16).	  Overall	  (first	  bar),	  42.9%	  resolve	  
in	  3	  days	  and	  71.4%	  resolve	  in	  7	  days.	  X	  axis	  shows	  the	  timeline,	  Y	  axis	  shows	  
the	  numbers	  of	  DVTs.	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Day	  3	  DVTs	  
	  
All patients underwent 3 scans on Days 1, 3 and 7 of ICU admission. Therefore, all 
patients with D3 incident DVT had only one more follow up scan at day7. Further follow up 
scans beyond that period was considered not feasible. Observations were similar to those 
encountered with the day 1 DVTs. By the day 7 scan (first follow up scan), as with the day 1 
DVTs, nearly half had spontaneously resolved (Table 5, Figure 5).  
 
	  
	  
Table	  5	  -­‐	  Course	  of	  Incident	  D3	  DVTs	  in	  the	  Medical	  ICU	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Figure	  5	  -­‐	  Course	  of	  D3	  DVTs	  
Overall	  
Lower	  Limb	  
Upper	  Limb	  
Mulkple	  sites	  
D3	  DVTs	  	   Resolution	  by	  D7	  
Lower	  Limb	  (n=20)	   7	  (35%)	  
Upper	  Limb	  (n=6)	   6	  (100%)	  
Multiple	  sites	  (n=2)	   -­‐	  
Catheter	  Related	  (n=19)	   9	  (47.3%)	  
Overall	  (n=28)	   13	  (46.4%)	  
	   	  
Figure	  5	  –	  Course	  of	  Day	  3	  Incident	  DVTs	  (n=35)	  encountered	  in	  the	  Medical	  ICU.	  
Overall	  (first	  bar),	  46.4%	  resolve	  over	  the	  subsequent	  3	  days.	  X	  axis	  shows	  the	  
timeline	  and	  Y	  axis	  shows	  the	  numbers	  of	  DVTs.	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CATHETER	  RELATED	  DVTS	  
	  
 Nearly two thirds of all DVTs were catheter related (Table 3). Amongst the lower limb 
DVTs, two thirds were catheter related and amongst the upper limb, it was eighty percent 
(Table 6). Femoral DVTs attributed to nearly three fourths of catheter related DVTs. The 
natural course of the catheter related DVTs was similar to that of the non catheter related ones 
on serial follow up (Tables 7-9, Figures 6-10).  
Table	  6	  -­‐	  Sites	  of	  DVTs	  -­‐	  Catheter	  related	  DVTs	  vs.	  Non	  catheter	  related	  DVTs	  
	   Catheter	  Related	  DVTs	  
(n=33)	  
Non	  Catheter	  Related	  DVTs	  
(n=18)	  
Lower	  Limb	  	   25	  (75.8%)	   14	  (77.8%)	  
Upper	  Limb	   8	  (24.2%)	   2	  (11.1%)	  
Multiple	  sites	   -­‐	   2	  (11.1%)	  
	  Table	  7	  -­‐	  Time	  of	  development	  of	  DVTs	  from	  the	  day	  of	  admission	  into	  the	  Medical	  ICU	  -­‐	  	  
Catheter	  Related	  vs.	  Non	  Catheter	  Related	  DVTs	  
DVT	  development	   Catheter	  Related	  DVTs	  
(n=33)	  
Non	  Catheter	  Related	  DVTs	  
(n=18)	  
Day	  1	   10	  (30.3%)	   6	  (33.3%)	  
Day	  3	   19	  (57.6%)	   9	  (50%)	  
Day	  7	   4	  (12.1%)	   3	  (16.7%)	  
Table	  8	  -­‐	  Course	  of	  D1	  DVTs	  -­‐	  Catheter	  Related	  vs.	  Non	  Catheter	  Related	  	  
Day	  1	  DVT	  
(n=16)	  
Catheter	  Related	  DVTs	  
(n=10)	  
Non	  Catheter	  Related	  DVTs	  
(n=6)	  
Resolution	  by	  D3	  	   5	  (50%)	   2	  (33.3%)	  
Resolution	  by	  D7	   8	  (80%)	   4	  (66.7%)	  
Table	  9	  -­‐	  Course	  of	  D3	  DVTs	  -­‐	  Catheter	  Related	  vs.	  Non	  Catheter	  Related	  	  
Day	  3	  DVT	  
(n=28)	  
Catheter	  Related	  DVTs	  
(n=19)	  
Non	  Catheter	  Related	  DVTs	  
(n=9)	  
Resolution	  by	  D7	   9	  (47.3%)	   4	  (44.4%)	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Figure	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  -­‐	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Figure	  7	  -­‐	  Day	  3	  DVTs	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Figure	  8	  -­‐	  Day	  7	  DVTs	  
Line	  Related	  
Non	  Line	  Related	  
Figure	  6	  –	  Catheter	  Related	  vs.	  Non	  Catheter	  related	  	  -­‐	  Amongst	  the	  Day	  1	  	  DVTs	  (n=16),	  62%	  were	  
catheter	  related	  ones.	  
Figure	  7	  –	  Catheter	  Related	  vs.	  Non	  Catheter	  Related	  -­‐	  Amongst	  the	  Day	  3	  	  DVTs	  (n=35),	  68%	  were	  
catheter	  related	  ones.	  
Figure	  8	  –	  Catheter	  Related	  vs.	  Non	  Catheter	  Related	  -­‐	  Amongst	  the	  Day	  7	  	  DVTs	  (n=7),	  57%	  were	  
catheter	  related	  ones.	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Figure	  10	  -­‐	  Course	  of	  D3	  DVTs	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Figure	  9	  –	  Course	  of	  the	  Catheter	  Related	  (n=10)	  vs.	  Non	  Catheter	  Related	  (n=6)	  Day	  1	  DVTs.	  X	  
axis	  shows	  the	  catheter	  related	  vs.	  non	  catheter	  related	  DVTs	  with	  the	  time	  catheter	  ;	  Y	  axis	  
shows	  the	  numbers	  of	  DVTs.	  
Figure	  10	  –	  Course	  of	  the	  Catheter	  Related	  (n=19)	  vs.	  Non	  Catheter	  Related	  (n=9)	  Day	  3	  DVTs.	  X	  
axis	  shows	  the	  catheter	  related	  vs.	  non	  catheter	  related	  DVTs	  with	  the	  time	  catheter	  ;	  Y	  axis	  
shows	  the	  numbers	  of	  DVTs.	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TYPE	  OF	  THROMBI	  ENCOUNTERED	  
	  
	   The thrombi encountered in our study were characterized based on their sonological 
characteristics into one of the following three types: 
1) Complete thrombosis* was characterized by complete lack of compressibility of 
the vein or visualization of the thrombus nearly causing total luminal occlusion or 
absence of flow in the colour flow imaging. 
2) Partial thrombosis** was characterized by partial luminal obstruction as evidenced 
by the vein being partially compressible or visualization of a thrombus partly 
occluding the lumen or colour flow imaging showing partial flow across the lumen. 
3) Small catheter related thrombus*** was characterized by the presence of echogenic 
small thrombus around the catheter precluding complete compressibility.  
Seventeen thrombi were encountered amongst the sixteen patients, in whom day 1 
DVT was identified (one patient had bilateral femoral DVT). It was surprising that one third of 
the DVTs encountered on the day of admission into MICU were attributed to complete 
thrombosis.  However, all the jugular thrombi were only small catheter related ones (Table 10) 
Amongst the 28 patients, in whom day 3 incident DVT was identified, 30 thrombi were 
encountered (Table 11). Two patients had thrombosis at multiple sites, one at femoral 
(complete) and popliteal (partial) and the other at femoral (small catheter related) and jugular 
(complete). Nearly half were small catheter related ones while the remaining were contributed 
equally by complete and partial thrombi. Almost all the jugular thrombi were small catheter 
related ones.  A similar trend was observed among the day 7 DVTs and the overall DVTs 
encountered in the study (Tables 12, 13). 
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Table	  10	  –	  Type	  of	  Thrombus	  encountered	  among	  the	  Day	  1	  DVTs	  
Day	  1	  DVTs	  
(n=17)	  
Complete	  
thrombosis*	  
Partial	  thrombosis	  
**	  
Small	  catheter	  
related	  
thrombus***	  
Total	  
Jugular	   -­‐	   -­‐	   2	  (100%)	   2	  (11.8%)	  
Femoral	   6	  (40%)	   1	  (6.7%)	   8	  (53.3%)	   15	  (88.2%)	  
Total	   6	  (35.3%)	   1	  (5.9%)	   10	  (58.8%)	   17	  
	  
	  
Table	  11	  –	  Type	  of	  Thrombus	  encountered	  among	  the	  Day	  3	  DVTs	  
Day	  3	  DVTs	  
(n=30)	  
Complete	  
thrombosis*	  
Partial	  thrombosis	  
**	  
Small	  catheter	  
related	  
thrombus***	  
Total	  
Jugular	   1	  (12.5%)	   -­‐	   7	  (87.5%)	   8	  (26.7%)	  
Femoral	   7	  (35%)	   7	  (35%)	   6	  (30%)	   20	  (66.7%)	  
Popliteal	   -­‐	   2	  (100%)	   -­‐	   2	  (6.6%)	  
Total	   8	  (26.7%)	   9	  (30%)	   13	  (43.3%)	   30	  
	  
	  
Table	  12	  –	  Type	  of	  Thrombus	  encountered	  among	  the	  Day	  7	  DVTs	  
Day	  7	  DVTs	  
(n=7)	  
Complete	  
thrombosis*	  
Partial	  thrombosis	  
**	  
Small	  catheter	  
related	  
thrombus***	  
Total	  
Jugular	   -­‐	   -­‐	   2	  (100%)	   2	  (28.6%)	  
Femoral	   2	  (40%)	   2	  (40%)	   1	  (20%)	   5	  (71.4%)	  
Total	   2	  (28.6%)	   2	  (28.6%)	   3	  (42.8%)	   7	  
	  
	  
Table	  13	  –	  Type	  of	  Thrombus	  encountered	  among	  the	  overall	  DVTs	  seen	  in	  our	  study	  
All	  thrombi	  
encountered	  	  
Complete	  
thrombosis	  
Partial	  
thrombosis	  	  
Small	  catheter	  
related	  
thrombus***	  
Total	  
Jugular	   1	  (8%)	   -­‐	   11	  (92%)	   12	  (22.2%)	  
Femoral	   15	  (37.5%)	   10	  (25%)	   15	  (37.5%)	   40	  (74.1%)	  
Popliteal	   -­‐	   2	  (100%)	   -­‐	   2	  (3.7%)	  
Total	   16	  (29.6%)	   12	  (22.2%)	   26	  (48.2%)	   54	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SECONDARY	  OUTCOMES:	  DEATH,	  DISCHARGE	  &	  DURATION	  OF	  HOSPITAL	  
STAY	  
	  
            The in-hospital mortality rate in the entire study group was 24.7% (n=54/219). Nearly 
three fourths of the in-hospital deaths occurred in the intensive care unit (n=42, 77.8%). 
Sudden deaths contributed to 16.7% (n=9) of the overall mortality in the hospital. A small 
percentage of patients were discharged against medical advice (n=14/219, 8.7%). The mean 
duration of ICU stay was 1 week and that of hospitalization was 2 weeks.  
            The results of a positive scan were conveyed to the treating physician, who decided 
further course of management, to their discretion. Most of them were observed till discharge, 
for  clinical evidence of DVT or its proximal propagation, with only 3 patients (8.57%) 
(amongst the 35 patients newly diagnosed with DVT in the medical ICU), being discharged 
with a diagnosis of DVT, having been initiated on oral anticoagulation therapy. It was 
presumed that the DVT detected in the remaining patients had spontaneously resolved. This 
was however, not confirmed, as serial scans following the day 7 scan was beyond the scope of 
the study due to feasibility constraints. All the three patients had been identified earlier during 
the study, with two of them being detected on day 3 and one on day 7. One of them had 
bilateral femoral thrombi, while the two others had jugular involvement in addition to femoral 
thrombi.  
INCIDENT	  DVT	  VS.	  NON	  DVT	  
	  
            A comparison between the secondary outcomes observed in the Incident DVT group 
(n=35) and the non DVT group (n=168) (Figures 11-14) showed that the mean duration of 
hospital stay was significantly higher in the DVT group (Table 14, Figures 15). The mean 
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duration of ICU stay at the development of DVT was 3.8 ± 1.6 days and the same for hospital 
stay was 7.2 ± 6.7 days. This signifies that the high risk period for DVT development was 
around the third day of ICU stay and around a week of hospital stay. The proportion of sudden 
deaths was more in the DVT group, however this observation was not statistically significant. 
There were no cases of confirmed pulmonary embolism in our study. However, amongst the 
nine sudden deaths, there was only one case of clinically suspected pulmonary embolism. This 
occurred in a patient with femoral and jugular thromboses.  
 
Table	  14	  –	  Comparison	  between	  the	  Secondary	  Outcomes	  observed	  in	  the	  Incident	  DVT	  
group	  vs.	  Non	  DVT	  group	  
Total	  
(n=203)	  
Incident	  DVT	  
group	  
(n=35)	  
Non	  DVT	  group	  
(n=168)	  
P	  value	  
Death	  
	  	  	  	  	  In	  hospital	  	  
	  	  	  	  	  In	  ICU	  
	  
9	  (25.7)	  
6	  (17.6)	  
	  
40	  (23.8)	  
31	  (18.7)	  
	  
0.81	  
0.85	  
Death	  –	  all	  cause	  
	  	  	  	  	  Sudden	  death	  
	  	  	  	  	  Confirmed	  /	  probable	  PE	  
	  	  	  	  	  Other	  causes	  
	  
3	  (33.3)	  
-­‐-­‐-­‐	  
6	  (66.7)	  
	  
6	  (15)	  
-­‐-­‐-­‐	  
34	  (85)	  
	  
0.19	  
	  
0.675	  
Discharge	  against	  medical	  advice	   4	  (11.8)	   14	  (8.4)	   0.55	  
Discharge	  diagnosis	  of	  DVT*	   3	  (8.6)	   -­‐-­‐-­‐	   <0.001	  
Mean	  duration	  of	  ICU	  stay	  (days)	  
Median	  &	  IQR	  
8.9	  ±	  6.1	  
7	  (4.75,	  12.25)	  
6.96	  ±	  5.3	  
5	  (4,9)	  
0.056	  
Mean	  duration	  of	  hospital	  stay	  (days)	  
Median	  &	  IQR	  
23.1	  ±	  18.3	  
20.5	  (10,25)	  
12.97	  ±	  8.5	  
10.5	  (7,	  16)	  
<0.001	  
Mean	  duration	  of	  ICU	  stay	  at	  
development	  of	  DVT	  (days)	  
3.8	  ±	  1.6	   	   	  
Mean	  duration	  of	  hospitalization	  at	  
development	  of	  DVT	  (days)	  
7.2	  ±	  6.7	   	   	  
*2	  patients	  had	  non	  catheter	  related	  DVT	  and	  one	  of	  them	  had	  a	  catheter	  related	  DVT	  
IQR-­‐	  Interquartile	  range	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Figure	  11	  –	  Secondary	  Outcomes	  in	  the	  Incident	  DVT	  (n=35)	  group.	  
Figure	  12	  –	  Secondary	  Outcomes	  in	  the	  Non	  DVT	  (n=168)	  group.	  
The	  secondary	  outcomes	  were	  largely	  similar	  in	  both	  the	  groups.	  	  
Figure	  13	  –	  Mortality	  in	  the	  Incident	  DVT	  (n=35)	  group.	  
Figure	  14	  –	  Mortality	  in	  the	  Non	  DVT	  (n=168)	  group.	  
Although,	  the	  proportion	  of	  sudden	  deaths	  was	  higher	  in	  the	  incident	  DVT	  group	  (33%	  vs.	  15%),	  
this	  difference	  was	  not	  statistically	  significant	  (p=0.19).	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Figure	  15	  –	  Duration	  of	  ICU	  stay	  and	  hospital	  stay	  –	  Incident	  DVT	  group	  (n=35)	  vs.	  Non	  DVT	  group	  
(n=168).	  Although	  both	  were	  longer	  in	  the	  DVT	  group,	  the	  duration	  of	  hospital	  stay	  was	  significantly	  
longer	  in	  the	  former	  (p<0.001)	  with	  a	  difference	  of	  10	  days	  between	  the	  median	  duration	  of	  
hospitalization	  between	  the	  	  2	  groups	  (20.5	  vs.	  10.5	  days)	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Table	  15	  –	  Comparison	  between	  the	  Secondary	  Outcomes	  observed	  in	  the	  Overall	  DVT	  
group	  vs.	  Non	  DVT	  group	  
Total	  
(n=219)	  
Overall	  DVT	  
group	  
(n=51)	  
Non	  DVT	  group	  
(n=168)	  
P	  Value	  
Death	  
	  	  	  	  	  In	  hospital	  (total)	  
	  	  	  	  	  In	  ICU	  
	  
14	  (28.6)	  
11	  (22.4)	  
	  
40	  (23.8)	  
31	  (18.7)	  
	  
0.59	  
0.62	  
Death	  –	  all	  cause	  
	  	  	  	  	  Sudden	  death	  
	  	  	  	  	  Confirmed	  /	  probable	  PE	  
	  	  	  	  	  Other	  causes	  
	  
3	  (21.4)	  
-­‐-­‐-­‐	  
11	  (78.6)	  
	  
6	  (15)	  
-­‐-­‐-­‐	  
34	  (85)	  
	  
0.46	  
	  
0.83	  
Discharge	  against	  medical	  advice	   5	  (10.2)	   14	  (8.4)	   0.74	  
Discharge	  diagnosis	  of	  DVT	   3	  (5.9)	   -­‐-­‐-­‐	   <0.002	  
Mean	  duration	  of	  ICU	  stay	  (days)	  
Median	  &	  IQR	  
7.9	  ±	  5.6	  
6	  (4,11)	  
6.96	  ±	  5.3	  
5	  (4,9)	  
0.274	  
Mean	  duration	  of	  hospital	  stay	  (days)	  
Median	  &	  IQR	  
20.1	  ±	  17.0	  
19	  (9,23.5)	  
12.97	  ±	  8.5	  
10.5	  (7,16)	  
<0.001	  
Mean	  duration	  of	  ICU	  stay	  at	  
development	  of	  DVT	  (days)	  
	  2.9	  ±	  1.9	   	   	  
Mean	  duration	  of	  hospitalization	  at	  
development	  of	  DVT	  (days)	  
	  
6.1	  ±	  6.5	  
	   	  
IQR=interquartile	  range	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Figure	  16	  –	  Secondary	  Outcomes	  in	  the	  Overall	  DVT	  (n=51)	  group.	  
Figure	  17	  –	  Mortality	  in	  the	  Overall	  DVT	  (n=51)	  group.	  
On	  comparing	  with	  figures	  12	  &	  14,	  the	  secondary	  outcomes	  appeared	  largely	  similar	  between	  
the	  2	  groups.	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SECONDARY	  OUTCOMES	  IN	  THE	  NON	  CATHETER	  RELATED	  DVT	  GROUP	  
	  
            Only one thirds of the incident DVTs were non-catheter related in our study. Catheter 
related DVTs were thought to be related to the presence of a central venous catheter and hence 
its natural course was thought to be dependent on the life of the catheter, with most of them 
being transient and resolving spontaneously. In contrast, the non-catheter related DVTs were 
thought to be more reflective of the dynamic changes in the coagulation system in the critically 
ill, which  favoured their development. Therefore, it was interesting to pitch the secondary 
outcomes seen in the incident non-catheter related DVT group against the non DVT group 
(Table 16). The duration of hospital stay was longer in the former, similar to the observations 
made earlier. 
Table	  16	  –	  Comparison	  between	  the	  Secondary	  outcomes	  observed	  in	  the	  Non	  catheter	  
related	  DVT	  group	  vs.	  Non	  DVT	  group	  
Total	  
(n=180)	  
Non	  catheter	  related	  
DVT	  
(n=12)	  
Non	  DVT	  group	  
(n=168)	  
P	  value	  
Death	  
	  	  	  	  	  In	  hospital	  	  
	  	  	  	  	  In	  ICU	  
	  
3	  (25)	  
2	  (16.7)	  
	  
40	  (24.1)	  
31	  (18.7)	  
	  
0.92	  
0.87	  
Death	  –	  all	  cause	  
	  	  	  	  	  Sudden	  death	  
	  	  	  	  	  Confirmed	  /	  probable	  PE	  
	  	  	  	  	  Other	  causes	  
	  
1	  (33.3)	  
-­‐-­‐-­‐	  
2	  (66.7)	  
	  
6	  (15)	  
-­‐-­‐-­‐	  
34	  (85)	  
	  
0.41	  
	  
0.76	  
Discharge	  against	  medical	  advice	   1	  (8)	   14	  (8.4)	   1.00	  
Discharge	  diagnosis	  of	  DVT	   2	  (16.7)	   -­‐-­‐-­‐	   <0.001	  
Mean	  duration	  of	  ICU	  stay	  (days)	  
Median	  &	  IQR	  
9.25	  ±	  8.24	  
6.5	  (3.25,	  14.75)	  
6.96	  ±	  5.3	  
5	  (4,9)	  
0.167	  
Mean	  duration	  of	  hospital	  stay	  (days)	  
Median	  &	  IQR	  
29.17	  ±	  15.32	  
25	  (22,	  36)	  
12.97	  ±	  8.5	  
10.5	  (7,16)	  
<0.001	  
Mean	  duration	  of	  ICU	  stay	  at	  
development	  of	  DVT	  (days)	  
4	  ±	  1.81	  
3	  (3,	  6)	  
	   	  
Mean	  duration	  of	  hospitalization	  at	  
development	  of	  DVT	  (days)	  
9.33	  ±	  6.21	  
7.5	  (4,	  13)	  
	   	  
IQR=interquartile	  range	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NON	  CATHETER	  RELATED	  DVT	  GROUP	  VS.	  CATHETER	  RELATED	  DVT	  GROUP	  
	  
            The secondary outcomes of the incident DVT group were compared between the non 
catheter related and the catheter related ones, in order to appreciate the differences with respect 
to their clinical outcomes (Table 17). There was no statistically significant difference between 
their outcomes. This was thought to be attributable to the small number of events in both the 
groups. However, the mean duration of hospital stay and the mean duration of hospitalization 
at the time of development of DVT appeared to be longer in the non catheter related DVT 
group. Although their p values were not statistically significant, they were less than 20% and 
hence it was thought that the difference might have been statistically significant had the event 
rate been higher. 
Table	  17	  –	  Comparison	  between	  the	  Secondary	  Outcomes	  observed	  in	  the	  Non	  catheter	  
related	  DVT	  group	  vs.	  catheter	  related	  DVT	  group	  
Total	  
(n=35)	  
Non	  catheter	  
related	  DVT	  
(n=12)	  
Catheter	  related	  
incident	  DVT	  
(n=23)	  
P	  value	  
Death	  
	  	  	  	  	  In	  hospital	  	  
	  	  	  	  	  In	  ICU	  
	  
3	  (25)	  
2	  (16.7)	  
	  
6	  (26.1)	  
4	  (17.4)	  
	  
0.94	  
0.95	  
Death	  –	  all	  cause	  
	  	  	  	  	  Sudden	  death	  
	  	  	  	  	  Confirmed	  /	  probable	  PE	  
	  	  	  	  	  Other	  causes	  
	  
1	  (33.3)	  
	  
2	  (66.7)	  
	  
2	  (33.3)	  
	  
4	  (66.7)	  
	  
0.97	  
	  
0.95	  
Discharge	  against	  medical	  advice	   1	  (8)	   3	  (13.04)	   0.67	  
Discharge	  diagnosis	  of	  DVT*	   2	  (16.7)	   1	  (4.35)	   0.21	  
Mean	  duration	  of	  ICU	  stay	  (days)	  
Median	  &	  IQR	  
9.25	  ±	  8.24	  
6.5	  (3.25,	  14.75)	  
8.77	  ±	  4.67	  
7.5	  (5,12.25)	  
0.826	  
Mean	  duration	  of	  hospital	  stay	  (days)	  
Median	  &	  IQR	  
29.17	  ±	  15.32	  
25	  (22,	  36)	  
19.77	  ±	  19.32	  
18.5	  (9.5,	  21)	  
0.154	  
Mean	  duration	  of	  ICU	  stay	  at	  
development	  of	  DVT	  (days)	  
4	  ±	  1.81	  
3	  (3,	  6)	  
3.70	  ±	  1.55	  
3	  (3,	  3)	  
0.61	  
Mean	  duration	  of	  hospitalization	  at	  
development	  of	  DVT	  (days)	  
9.33	  ±	  6.21	  
7.5	  (4,	  13)	  
6.13	  ±	  6.81	  
4	  (3,	  7)	  
0.183	  
IQR=interquartile	  range	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RISK	  FACTOR	  ANALYSIS	  
	  
RISK	  FACTORS	  FOR	  DEVELOPMENT	  OF	  DVT	  IN	  THE	  MEDICAL	  ICU	  
	  
            . One of the objectives of the study was to determine the risk factors unique to 
development of DVT in the critically ill medical patients. As the risk factors would have to be 
indigenous to the ICU setting (implying adequate exposure to the ICU risk factors which 
would in turn require a minimum period of ICU stay of atleast 48 hours), the day 1 DVTs were 
excluded from the risk factor analysis. Bivariate analysis (Table 18) revealed the following to 
be the statistically significant risk factors for development of DVT in the Medical ICU: 
1) Central Venous Catheter, RR=15.67 (2.11, 111.85) 
2) Age more than 40 years, RR=2.43 (1.16, 5.08) 
3) Vasopressors, RR=2.19 (1.11, 4.34) 
4) Day3 PT (p=0.003) & INR (p<0.001) 
            Age was directly related to the development of DVT. Gender was not significant 
although, the males seemed to be at a lesser risk for developing DVT (0.76, (0.42, 1.4)). 
Amongst the exposure risk factors, there was no statistically significant difference between the 
two groups. Although, the insertion of a pacemaker appeared to be a risk factor with a relative 
risk of 1.96 (0.38, 10.0), it was not statistically significant. All the effect modifiers (aspirin, 
clopidogrel, vitamin K) appeared to be protective against the development of DVT, although, 
there was no statistical significance. Most of the DVTs encountered in the MICU were 
asymptomatic with only 2 patients exhibiting clinical features suggestive of DVT (erythema 
and swelling).  
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            The presence of central venous catheters appeared to confer the highest risk. Amongst 
the central venous catheters, it was seen that a femoral catheter, on its own, conferred a risk of 
2.35 (1.30, 4.25). Similar observations were also made amongst the dialysis ports, wherein, a 
femoral port conferred a risk of 2.65 (1.25, 5.59), although the former per se was not a 
statistically significant risk factor. The duration of central venous catheters was also 
significantly associated with the development of DVT. Amongst the vasopressors, which had 
conferred a risk of 2.19 (1.11, 4.34), the use of multiple vasopressors conferred the highest risk 
(2.13, (1.77, 3.88)). Although the platelet transfusions appeared to confer a risk of 4.0 (0.66, 
23.98), this was not statistically significant. Amongst the bleeding parameters, PT and INR on 
day 3 were found to be significant factors affecting the development of DVT.  
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Table	  18	  –	  Bivariate	  Analysis	  –	  Risk	  factors	  associated	  with	  development	  of	  DVT	  in	  MICU	  
Risk	  factors	  
(n=203)	  
DVT	  group	  
(n=35)	  
n	  (%)	  
Non	  DVT	  
group	  
(n=168)	  
n	  (%)	  
Relative	  
Risk	  	  
95%	  CI	   P	  value	  
	  
Mean	  Age	  (yrs)	  
Age	  >40	  yrs	  
Age	  <40	  yrs	  
	  
	  
51.0	  ±	  14.7	  
27	  (23.0)	  
8	  (9.0)	  
	  
	  
43.9	  ±	  17.8	  
91	  (77.0)	  
77	  (91.0)	  
	  
	  
	  
2.43	  
	  
1.35,	  12.71	  
1.16,	  5.08	  
	  
0.016	  
0.020	  
	  
Male	  gender	  (n=112)	  
Female	  gender	  (n=91)	  
	  
	  
17	  (15.2)	  
18	  (19.78)	  
	  
95	  (84.8)	  
73	  (80.22)	  
	  
0.767	  
	  
0.42,	  1.40	  
	  
0.498	  
	  
Past	  history	  
	  	  	  	  	  Surgery	  (within	  4	  wks)	  (n=13)	  
	  	  	  	  	  Trauma	  (within	  4	  wks)	  (n=3)	  
	  	  	  	  	  Hospitalization	  (>3days)	  (n=35)	  
	  	  	  	  	  Central	  catheters	  (n=4)	  
	  	  	  	  	  NSAID	  use	  (n=2)	  
	  	  	  	  	  Rheumatic	  /	  autoimmune	  	  	  	  	  	  	  
	  	  	  	  	  (n=11)	  
	  
	  
	  
2	  (15.38)	  
-­‐-­‐-­‐	  
5	  (14.29)	  
2	  (50)	  
-­‐-­‐-­‐	  
1	  (9.09)	  
	  
	  
	  
11	  (84.62)	  
3	  (100)	  
30	  (85.71)	  
2	  (50)	  
2	  (100)	  
10	  (90.91)	  
	  
	  
	  
0.885	  
	  
0.80	  
1.00	  
	  
0.51	  
	  
	  
0.24,	  3.29	  
	  
0.33,	  1.92	  
	  
	  
0.08,	  3.41	  
	  
	  
0.844	  
	  
0.792	  
	  
	  
0.744	  
	  
Present	  history	  	  
	  	  	  	  	  Congestive	  cardiac	  failure(n=9)	  
	  	  	  	  	  Chronic	  liver	  failure	  (n=7)	  
	  	  	  	  	  Chronic	  kidney	  disease	  (n=13)	  
	  	  	  	  	  Malignancy	  (n=1)	  
	  	  	  	  	  Post	  partum	  (n=7)	  
	  	  	  	  	  Immobilization	  (n=6)	  
	  	  	  	  	  Pacemaker	  Insertion	  (n=3)	  
	  	  	  	  	  Smoking	  (n=31)	  
	  	  	  	  	  Alcohol	  (n=46)	  
	  	  	  	  	  Aspirin	  (n=23)	  
	  	  	  	  	  Clopidogrel	  (n=18)	  
	  	  	  	  	  Vitamin	  K	  supplements	  (n=32)	  
	  	  	  	  	  Other	  comorbidities	  (n=93)	  
	  
	  
	  
	  
1	  (11.11)	  
1	  (14.29)	  
1	  (7.69)	  
-­‐-­‐-­‐	  
1	  (14.29)	  
1	  (16.67)	  
1	  (33.33)	  
5	  (16.13)	  
6	  (13.04)	  
2	  (8.7)	  
3	  (16.67)	  
4	  (12.5)	  
20	  (21.51)	  
	  
	  
	  
8	  (88.89)	  
6	  (85.71)	  
12	  (92.31)	  
1	  (100)	  
6	  (85.71)	  
5	  (83.33)	  
2	  (66.67)	  
26	  (83.87)	  
40	  (86.96)	  
21	  (91.3)	  
15	  (83.33)	  
28	  (87.5)	  
73	  (78.49)	  
	  
	  
	  
0.634	  
0.823	  
0.429	  
	  
0.824	  
0.965	  
1.96	  
0.925	  
0.706	  
0.474	  
0.964	  
0.689	  
1.58	  
	  
	  
0.09,	  4.13	  
0.13,	  5.19	  
0.06,	  2.90	  
	  
0.13,	  5.19	  
0.15,	  5.93	  
0.38,	  10.0	  
0.39,	  2.20	  
0.31,	  1.60	  
0.12,	  1.85	  
0.33,	  2.84	  
0.26,	  1.80	  
0.85,	  2.90	  
	  
	  
0.963	  
0.765	  
0.573	  
	  
0.765	  
0.609	  
0.978	  
0.936	  
0.525	  
0.390	  
0.795	  
0.604	  
0.196	  
	  
SOFA	  score	  at	  admission	  to	  ICU	  
	  
	  
7.7	  ±	  3.4	  
	  
6.9	  ±	  4.3	  
	  
	   	  
-­‐0.68,	  2.37	  
	  
0.277	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Symptoms	  of	  DVT	  (n=6)	   2	  (33.3)	   4	  (66.7)	   1.98	   0.61,	  6.43	   0.609	  
	  
	  
Treatment	  in	  ICU	  
	  	  	  	  	  Central	  Venous	  
catheters(n=139)	  
	  	  	  	  	  	  	  	  	  	  Internal	  Jugular	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Subclavian	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Femoral	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  PIC	  catheters*	  (n=3)	  
	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Dialysis	  ports	  (n=14)	  
	  	  	  	  	  	  	  	  	  	  Jugular	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Femoral	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Mechanical	  ventilation(n=154)	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Sedatives	  (n=126)	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  	  
	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  Vasopressors	  (n=108)	  
	  	  	  	  	  	  	  	  	  	  Dopamine	  
	  	  	  	  	  	  	  	  	  	  Adrenaline	  
	  	  	  	  	  	  	  	  	  	  Noradrenaline	  
	  	  	  	  	  	  	  	  	  	  Dobutamine	  
	  	  	  	  	  	  	  	  	  	  Multiple	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  
	  
34	  (24.46)	  
	  	  	  	  	  15	  (21.13)	  
	  	  	  	  	  	  	  	  	  	  13	  (19.1)	  
	  	  	  	  	  	  	  	  	  	  2	  (66.67)	  
	  	  	  	  	  1(20)	  
	  	  	  	  	  	  	  	  	  	  -­‐-­‐-­‐	  
	  	  	  	  	  	  	  	  	  	  1	  (2.9)	  
	  	  	  	  	  18	  (28.57)	  
	  	  	  	  	  	  	  	  	  	  18	  (52.9)	  
	  	  	  	  	  	  	  	  	  	  -­‐-­‐-­‐	  
8.2	  ±	  3.3	  
	  
1	  (33.33)	  
	  	  	  	  	  1	  (100)	  
	  	  	  	  	  -­‐-­‐-­‐	  
10.0	  
	  
5	  (35.71)	  
	  	  	  	  	  -­‐-­‐-­‐	  
	  
	  
	  	  	  	  	  5	  (41.67)	  
	  	  	  	  	  	  	  	  	  	  1	  (20)	  
	  	  	  	  	  	  	  	  	  	  4	  (57.14)	  
9.8	  ±	  4.1	  
	  
25	  (16.23)	  
8.0	  ±	  4.9	  
	  
19	  (15.08)	  
4.2	  ±	  2.2	  
	  
25	  (23.15)	  
	  	  	  	  	  1	  (33.33)	  
	  	  	  	  	  5	  (20.83)	  
	  	  	  	  	  6	  (17.14)	  
	  	  	  	  	  -­‐-­‐-­‐	  
	  	  	  	  	  13	  (29.55)	  
4.0	  ±	  2.1	  
	  
5	  (17.86)	  
	  
	  
105	  (75.54)	  
	  	  	  	  	  56	  (78.87)	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  55	  (80.9)	  
	  	  	  	  	  	  	  	  	  	  1	  (33.33)	  
	  	  	  	  	  4	  (80)	  
	  	  	  	  	  	  	  	  	  	  4	  (3.8)	  
	  	  	  	  	  	  	  	  	  	  -­‐-­‐-­‐	  
	  	  	  	  	  45	  (71.43)	  
	  	  	  	  	  	  	  	  	  	  42	  (40.0)	  
	  	  	  	  	  	  	  	  	  	  3	  (2.9)	  
6.96	  ±	  2.97	  
	  
2	  (66.67)	  
	  	  	  	  	  1	  (50)	  
	  	  	  	  	  1	  (50)	  
5.5	  ±	  0.7	  
	  
9	  (64.29)	  
	  	  	  	  	  2	  (22.2)	  
	  	  	  	  	  	  	  	  	  	  -­‐-­‐-­‐	  
	  	  	  	  	  	  	  	  	  	  2	  (22.2)	  
	  	  	  	  	  7	  (58.33)	  
	  	  	  	  	  	  	  	  	  	  4	  (80)	  
	  	  	  	  	  	  	  	  	  	  3	  (42.86)	  
8.4	  ±	  4.9	  
	  
129	  (83.77)	  
7.3	  ±	  5.2	  
	  
107	  (84.92)	  
3.6	  ±	  2.7	  
	  
83	  (76.85)	  
	  	  	  	  	  2	  (66.67)	  
	  	  	  	  	  19	  (79.17)	  
	  	  	  	  	  29	  (82.86)	  
	  	  	  	  	  2	  (2.4)	  
	  	  	  	  	  31	  (70.45)	  
4.0	  ±	  2.9	  
	  
23	  (82.14)	  
	  
	  
15.65	  
1.39	  
1.17	  
4.04	  
1.16	  
	  
	  
2.35	  
2.52	  
	  
	  
	  
1.96	  
	  
	  
	  
	  
2.25	  
	  
	  
	  
2.65	  
1.16	  
3.61	  
	  
	  
0.795	  
	  
	  
0.725	  
	  
	  
2.19	  
1.96	  
1.24	  
0.99	  
	  
2.13	  
	  
	  
1.04	  
	  
	  
2.11,	  111.85	  
0.76,	  2.55	  
0.63,	  2.18	  
1.71,	  9.53	  
0.20,	  6.90	  
	  
	  
1.30,	  4.25	  
1.39,	  4.55	  
	  
0.019,	  2.41	  
	  
0.38,	  10.0	  
	  
	  
-­‐6.5,	  15.5	  
	  
1.03,	  4.88	  
	  
	  
	  
1.25,	  5.59	  
0.20,	  6.90	  
1.76,	  7.41	  
-­‐4.27,	  6.98	  
	  
0.41,	  1.54	  
-­‐1.49,	  2.93	  
	  
0.40,	  1.32	  
-­‐0.79,	  1.84	  
	  
1.11,	  4.34	  
0.38,	  10.0	  
0.53,	  2.90	  
0.44,	  2.21	  
	  
1.17,	  3.88	  
-­‐1.28,	  1.21	  
	  
0.44,	  2.46	  
	  
	  
<0.001	  
0.378	  
0.760	  
0.07	  
0.66	  
	  
	  
0.007	  
0.003	  
	  
0.047	  
	  
0.978	  
	  
	  
0.121	  
	  
0.126	  
	  
	  
	  
0.05	  
0.66	  
0.02	  
0.609	  
	  
0.647	  
0.520	  
	  
0.394	  
0.433	  
	  
0.028	  
0.978	  
0.834	  
0.818	  
	  
0.03	  
0.954	  
	  
0.859	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No	  comparisons	  were	  made	  as	  one	  of	  the	  arms	  either	  had	  complete	  absence	  of	  the	  risk	  factor,	  or	  the	  
occurrence	  was	  equal	  in	  both	  the	  arms.	  
IQR=interquartile	  range,	  SD=standard	  deviation,	  PIC=peripherally	  inserted	  central	  catheters.	  
PT	  and	  APTT	  have	  been	  given	  in	  seconds	  and	  platelets	  in	  lakhs.	  
	  
	  
	  
	  	  	  	  	  Transfusions	  (n=28)	  
	  	  	  	  	  	  	  	  	  Packed	  cells	  
	  	  	  	  	  	  	  	  	  Whole	  blood	  
	  	  	  	  	  	  	  	  	  Platelets	  
	  	  	  	  	  	  	  	  	  Cryoprecipitate	  
	  	  	  	  	  	  	  	  	  Multiple	  
	  
	  	  	  	  	  1	  (12.5)	  
	  	  	  	  	  1	  (20)	  
	  	  	  	  	  1	  (25)	  
	  	  	  	  	  -­‐-­‐-­‐	  
	  	  	  	  	  2	  (16.67)	  
	  	  	  	  	  7	  (87.5)	  
	  	  	  	  	  -­‐-­‐-­‐	  
	  	  	  	  	  3	  (75)	  
	  	  	  	  	  3	  (13)	  
	  	  	  	  	  10	  (83.33)	  
0.716	  
	  
4.00	  
	  
0.96	  
0.11,	  4.60	  
	  
0.66,	  23.98	  
	  
0.26,	  3.55	  
0.908	  
	  
0.636	  
	  
0.734	  
	  
Laboratory	  investigations	  
	  	  	  	  	  Mean	  PT	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  	  	  	  	  Mean	  INR	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  	  	  	  	  Mean	  APTT	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  	  	  	  	  Mean	  platelet	  counts	  
	  	  	  	  	  	  	  	  	  	  D1	  (mean,	  SD)	  
	  	  	  	  	  	  	  	  	  	  (Median,	  IQR)	  
	  	  	  	  	  	  	  	  	  	  D3	  (mean,	  SD)	  
	  	  	  	  	  	  	  	  	  	  (Median,	  IQR)	  
	  	  	  	  	  	  	  	  	  	  D7	  (mean,	  SD)	  
	  	  	  	  	  	  	  	  	  	  (Median,	  IQR)	  
	  
	  
	  
	  
14.2	  ±	  3.1	  
16.1	  ±	  9.4	  
12.7	  ±	  2.2	  
	  
1.3	  ±	  0.3	  
1.5	  ±	  0.9	  
1.2	  ±	  0.2	  
	  
33.4	  ±	  7.9	  
37.3	  ±	  14.8	  
32.97	  ±	  9.6	  
	  
2.49L	  ±	  1.76L	  
2.07L(1.2,3.45)	  
2.01L	  ±	  1.56L	  
1.75L(0.63,2.8)	  
1.87L	  ±	  1.17L	  
1.58L(1.03,2.67)	  
	  
	  
	  
	  
14.0	  ±	  6.0	  
13.3	  ±	  3.6	  
12.6	  ±	  4.1	  
	  
1.3	  ±	  0.5	  
1.2	  ±	  0.3	  
1.1	  ±	  0.3	  
	  
32.9	  ±	  12.7	  
32.8	  ±	  12.7	  
32.0	  ±	  10.6	  
	  
2.14L	  ±	  1.35L	  
2.1L(1.04,3.07)	  
2.25L	  ±	  2.53L	  
1.89L(0.8,2.86)	  	  
1.91L	  ±	  1.23L	  
1.83L(0.93,2.6)	  
	  
	  
	  
	  
	  
-­‐1.85,	  2.25	  
0.94,	  4.65	  
-­‐1.30,	  1.50	  
	  
	  
0.13,	  0.468	  
-­‐0.04,	  0.20	  
	  
-­‐3.90,	  4.90	  
-­‐0.29,	  9.29	  
-­‐2.85,	  4.79	  
	  
-­‐0.17,	  0.87	  
	  
-­‐1.11,	  0.64	  
	  
-­‐0.48,	  0.40	  
	  
	  
	  
0.88	  
0.003	  
0.888	  
	  
	  
<0.001	  
0.06	  
	  
0.823	  
0.065	  
0.617	  
	  
0.191	  
	  
0.599	  
	  
0.853	  
	  
Thromboprophylaxis	  
	  	  	  	  	  Pharmacological	  
	  	  	  	  	  	  	  	  	  	  Heparin	  
	  	  	  	  	  	  	  	  	  	  Enoxaparin	  
	  	  	  	  	  	  	  	  	  	  Adequate	  dosage	  
	  	  	  	  	  Mechanical	  
	  	  	  	  	  Both	  
	  
	  
35	  (17.2)	  
	  	  	  	  	  19	  (16.67)	  
	  	  	  	  	  	  	  	  	  	  18	  (16.7)	  
	  	  	  	  	  	  	  	  	  	  1	  (16.67)	  
	  	  	  	  	  	  	  	  	  	  19	  (100)	  
	  	  	  	  	  16	  (19.05)	  
	  	  	  	  	  -­‐-­‐-­‐	  
	  
168	  (82.8)	  
	  	  	  	  	  95	  (83.33)	  
	  	  	  	  	  	  	  	  	  	  90	  (83.3)	  
	  	  	  	  	  	  	  	  	  	  5	  (83.3)	  
	  	  	  	  	  	  	  	  	  	  95	  (100)	  
	  	  	  	  	  68	  (80.95)	  
	  	  	  	  	  5	  (3.0)	  
	  
	  
	  
0.927	  
0.93	  
0.965	  
	  
1.19	  
	  
	  
	  
	  
0.51,	  1.70	  
0.51,	  1.70	  
0.16,	  5.93	  
	  
0.65,	  2.18	  
	  
	  
0.953	  
0.964	  
0.609	  
	  
0.701	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INDEPENDENT	  RISK	  FACTORS	  FOR	  DEVELOPMENT	  OF	  DVT	  IN	  THE	  MEDICAL	  ICU	  
	  
 Multivariate analysis included the risk factors which were significantly associated with 
the development of DVT. In addition to age, central venous catheters, vasopressors and day 3 
INR; SOFA score was also included in the analysis to adjust for severity of comorbidities.  
Central venous catheters emerged as the sole independent risk factor (Table 19). Age and day 
3 INR were also found to confer additional risk in the development of DVT, but were not 
statistically significant. This model was found to predict 20% of the variability (based on the R 
square value) and was also found to be of adequate fit (Hosmer Lemeshow test value >0.05). 
 
Table	  19	  -­‐	  Multivariate	  Analysis	  -­‐	  Risk	  factors	  for	  Development	  of	  DVT	  in	  MICU	  –	  Model	  1	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   15.97	   1.88,	  135.84	   0.01	  
2.	   Day	  3	  INR	   2.16	   0.87,	  5.34	   0.09	  
3.	   Age	  >	  40	  yrs	   2.05	   0.79,	  5.34	   0.14	  
4.	   Vasopressors	   1.01	   0.36,	  2.88	   0.93	  
5.	   SOFA	   0.95	   0.85,	  1.06	   0.34	  
Nagelkerke	  R	  Square	  =	  0.209,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.347	  (good	  fit)	  
 
Similar modeling was done with the substitution of day 3 PT instead of INR, which 
also yielded similar results (Table 20). This model was also found to be of adequate fit.  
Table	  20	  -­‐	  Multivariate	  Analysis	  -­‐	  Risk	  factors	  for	  Development	  of	  DVT	  in	  MICU	  –	  Model	  2	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   16.13	   1.89,	  137.25	   0.01	  
2.	   Day	  3	  PT	   1.07	   0.98,	  1.16	   0.09	  
3.	   Age	  >	  40	  yrs	   2.03	   0.78,	  5.29	   0.15	  
4.	   Vasopressors	   0.99	   0.35,	  2.83	   0.99	  
5.	   SOFA	   0.95	   0.85,	  1.06	   0.34	  
Nagelkerke	  R	  Square	  =	  0.209,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.218	  (good	  fit)	  
 The addition of clinically relevant factors to the above models (Tables 15 & 16) paved 
way to models 3 & 4 (Tables 21 & 22). Male gender and the effects modifiers commonly 
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encountered in our study, namely aspirin and vitamin K, were the additional factors which 
were analyzed. Addition of these factors also appeared to increase the predictive ability of the 
model by nearly 10%. It was of interest that, in these models, in addition to central venous 
catheters; day 3 PT/INR and vitamin K administration emerged as statistically significant 
factors, independently associated with the development of DVT. The latter was protective 
against DVT and this was thought to be related to the  underlying anticoagulant state in 
patients necessitating administration of vitamin K. Age more than forty years also emerged as 
a risk factor tending towards statistical significance (p=0.07). Both the models were found to 
be of adequate fit.  
Table	  21	  -­‐	  Multivariate	  Analysis	  -­‐	  Risk	  factors	  for	  Development	  of	  DVT	  in	  MICU	  –	  Model	  3	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   13.72	   1.59,	  118.48	   0.02	  
2.	   Day	  3	  INR	   4.23	   1.15,	  15.61	   0.03	  
3.	   Age	  >	  40	  yrs	   2.57	   0.93,	  7.13	   0.07	  
4.	   Vasopressors	   1.19	   0.39,	  3.59	   0.74	  
5.	   SOFA	   0.95	   0.85,	  1.06	   0.39	  
6.	   Male	  Sex	   1.30	   0.55,	  3.10	   0.54	  
7.	   Vitamin	  K	  	   0.17	   0.03,	  0.92	   0.04	  
8.	   Aspirin	   0.29	   0.06,	  1.47	   0.14	  
Nagelkerke	  R	  Square	  =	  0.278,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.415	  (good	  fit)	  
Table	  22	  -­‐	  Multivariate	  Analysis	  -­‐	  Risk	  factors	  for	  Development	  of	  DVT	  in	  MICU	  –	  Model	  4	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   13.91	   1.61,	  120.05	   0.02	  
2.	   Day	  3	  PT	   1.15	   1.02,	  1.29	   0.03	  
3.	   Age	  >	  40	  yrs	   2.54	   0.91,	  7.08	   0.07	  
4.	   Vasopressors	   1.17	   0.39,	  3.51	   0.78	  
5.	   SOFA	   0.95	   0.85,	  1.07	   0.40	  
6.	   Male	  Sex	   1.29	   0.55,	  3.09	   0.55	  
7.	   Vitamin	  K	  	   0.16	   0.03,	  0.88	   0.03	  
8.	   Aspirin	   0.30	   0.06,	  1.49	   0.14	  
Nagelkerke	  R	  Square	  =	  0.279,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.32	  (good	  fit)	  
	   The fifth model (Table 23) was drawn by the inclusion of the relatively significant 
exposure variables to the fourth model. As none of the exposure variables were statistically 
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significant as risk factors on the bivariate analysis, two of those with the least p values were 
included to study their influence on the development of DVT. Amongst the exposure variables, 
alcohol, smoking and vitamin K were the ones commonly encountered in the entire study 
population. The variables which were relatively significant on the bivariate analysis were 
chronic kidney disease (p=0.57) and alcohol consumption (p=0.52). The observations however 
did not differ from the previous model although, this seemed to have the best predictive value. 
Table	  23	  -­‐	  Multivariate	  Analysis	  -­‐	  Risk	  factors	  for	  Development	  of	  DVT	  in	  MICU	  –	  Model	  4	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   14.0	   1.61,	  122.12	   0.02	  
2.	   Day	  3	  PT	   1.14	   1.02,	  1.29	   0.02	  
3.	   Age	  >	  40	  yrs	   2.81	   0.99,	  7.97	   0.05	  
4.	   Vasopressors	   1.11	   0.37,	  3.38	   0.85	  
5.	   SOFA	   0.95	   0.85,	  1.07	   0.39	  
6.	   Male	  Sex	   1.08	   0.41,	  2.88	   0.88	  
7.	   Vitamin	  K	  	   0.15	   0.03,	  0.82	   0.03	  
8.	   Aspirin	   0.29	   0.06,	  1.52	   0.31	  
9.	   Chronic	  Kidney	  Disease	   0.32	   0.04,	  2.88	   0.31	  
10.	   Alcohol	   0.57	   0.15,	  2.13	   0.40	  
Nagelkerke	  R	  Square	  =	  0.293,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.89	  (good	  fit)	  
	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  18	  -­‐	  Risk	  factors	  for	  DVT	  in	  MICU	  
Age	  >	  40	  yrs	  
RR=2.43	  
(p=0.016)	  
SOFA	  	  
(p=0.28)	  
Central	  Venous	  
Catheters,	  RR=15.65	  
(p<0.001)	  
Vasopressors	  
RR=2.19	  
(p=0.03)	  
Day3	  INR	  
(p<0.001)	  
Central	  Venous	  Catheter,	  RR=15.97,	  p=0.01	  
Bivariate	  Analysis	  
Multivariate	  Analysis	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RISK	  FACTORS	  FOR	  THE	  DEVELOPMENT	  OF	  NON	  CATHETER	  RELATED	  DVT	  IN	  THE	  
MEDICAL	  ICU	  
	  
 The presence of central venous catheters had been seen in 154 patients (70.2 % of the 
study population). 24.4% (n=34/139) of patients on central venous catheters had developed 
DVT in the MICU.  Of those who had developed a DVT in the MICU, 97.1% (n=34/35) had a 
central venous catheter. In the non DVT group, this was seen in 62.5% patients (n=105/168).  
In the bivariate analysis of risk factors for development of DVT in the MICU, the 
strongest risk factor had been the presence of a central venous catheter (15.65, (2.11, 111.8)), 
which had again emerged as the only factor independently associated with DVT development 
on logistic regression. Further, the catheter related DVTs had contributed to nearly two-thirds 
of the incident DVTs (n=23/35). Therefore, this was thought to have had a large influence on 
the distribution of risk factors, although the secondary outcomes were apparently similar in 
patients with catheter related and non-catheter related DVTs.  
Hence, risk factor analysis of the non catheter related DVTs was done in order to 
identify the other risk factors involved in their development. The large number of catheter 
related DVTs and hence, the strong association with the presence of central venous catheters, 
was thought to have overshadowed the other factors. The bivariate analysis (Table 24) 
identified the following risk factors for the development of a catheter related DVT in the 
MICU: 
1) Central venous catheter, RR = 6.06 (0.8, 45.9), p=0.08 
2) Age > 40 years, RR = 3.9 (0.88, 17.2), p=0.095 
3) Day 3 PT (p=0.08) & INR (p=0.09) 
4) Day 1 platelet counts (p=0.006) 
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 The ones which were statistically significant (p<0.05) included the presence of a 
jugular catheter (3.62, (1.14, 11.57)), mean duration of central venous catheter and the platelet 
counts on day1. As the number of variates that had emerged statistically significant (in the 
bivariate analysis) was very small, all risk factors with a p value of less than 10% (above 
listed) were considered for the multivariate analysis (Table 24). It was interesting to note that 
among the central venous catheters, the femoral catheters seemed to confer the strongest risk 
to the development of DVT in MICU, while the jugular catheters appeared to be strongly 
implicated in the development of non catheter related DVT.  
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Table	  24–Bivariate	  Analysis-­‐Risk	  factors	  for	  development	  of	  non	  catheter	  related	  DVT	  in	  
MICU	  
Risk	  factors	  
(n=203)	  
Incident	  Non	  
catheter	  
related	  DVT	  
(n=12)	  
n	  (%)	  
Non	  DVT	  
(n=168)	  
n	  (%)	  
RR	   95%	  CI	   P	  value	  
	  
Mean	  Age	  (yrs)	  
Age	  <40	  yrs	  
Age	  >40	  yrs	  
	  
	  
53	  ±	  13.07	  
2	  (2.5)	  
10	  (10)	  
	  
43.99	  ±	  17.84	  
77	  (97.5)	  
91	  (90)	  
	  
	  
	  
3.91	  
	  
	  
	  
0.88,	  17.24	  
	  
	  
	  
0.095	  
	  
Male	  gender	  	  
Female	  gender	  	  
	  
	  
6	  (6)	  
6	  (8)	  
	  
95	  (94)	  
73	  (92)	  
	  
0.78	  
	  
0.26,	  2.33	  
	  
0.88	  
	  
Past	  history	  
	  	  	  	  	  Surgery	  (within	  4	  wks)	  	  
	  	  	  	  	  Trauma	  (within	  4	  wks)	  	  
	  	  	  	  	  Hospitalization	  (>3days)	  	  
	  	  	  	  	  Central	  catheters	  	  
	  	  	  	  	  NSAID	  use	  	  
	  	  	  	  	  Rheumatic	  /	  autoimmune	  disease	  	  
	  
	  
	  
1	  (8)	  
-­‐-­‐-­‐	  
4	  (12)	  
2	  (50)	  
-­‐-­‐-­‐	  
1	  (10)	  
	  
	  
11	  (92)	  
3	  (100)	  
30	  (88)	  
2	  (50)	  
2	  (100)	  
10	  (90)	  
	  
	  
1.27	  
	  
2.14	  
	  
	  
1.40	  
	  
	  
0.18,	  9.04	  
	  
0.69,	  6.72	  
	  
	  
0.20,	  9.86	  
	  
	  
0.719	  
	  
0.346	  
	  
	  
0.77	  
	  
Present	  history	  	  
	  	  	  	  	  Congestive	  cardiac	  failure	  	  
	  	  	  	  	  Chronic	  liver	  failure	  	  
	  	  	  	  	  Chronic	  kidney	  disease	  	  
	  	  	  	  	  Malignancy	  	  
	  	  	  	  	  Post	  partum	  	  
	  	  	  	  	  Immobilization	  (stroke/paresis)	  	  
	  	  	  	  	  Pacemaker	  Insertion	  	  
	  	  	  	  	  	  Smoking	  	  
	  	  	  	  	  	  Alcohol	  	  
	  	  	  	  	  	  Aspirin	  	  
	  	  	  	  	  	  Clopidogrel	  	  
	  	  	  	  	  	  Vitamin	  K	  supplements	  	  
	  	  	  	  	  	  Other	  comorbidities	  	  
	  
	  
	  
-­‐-­‐-­‐	  
-­‐-­‐-­‐	  
1	  (8)	  
-­‐-­‐-­‐	  
-­‐-­‐-­‐	  
1	  (17)	  
-­‐-­‐-­‐	  
3	  (10)	  
3	  (7)	  
1	  (5)	  
1	  (6)	  
-­‐-­‐-­‐	  
6	  (8)	  
	  
	  
8	  (100)	  
6	  (100)	  
12	  (92)	  
1	  (100)	  
6	  (100)	  
5	  (83)	  
2	  (100)	  
26	  (90)	  
40	  (93)	  
21	  (95)	  
15	  (94)	  
28	  (100)	  
73	  (92)	  
	  
	  
	  
	  
1.16	  
	  
	  
2.63	  
	  
1.73	  
1.06	  
0.65	  
0.93	  
	  
1.27	  
	  
	  
	  
	  
0.16,	  8.35	  
	  
	  
0.40,	  17.25	  
	  
0.50,	  6.02	  
0.30,	  3.74	  
0.08,	  4.81	  
0.12,	  6.76	  
	  
0.43,	  3.81	  
	  
	  
	  
	  
0.67	  
	  
	  
0.867	  
	  
0.645	  
0.797	  
0.975	  
0.649	  
	  
0.888	  
	  
SOFA	  score	  at	  admission	  to	  ICU	  
	  
	  
7.75	  ±	  1.14	  
	  
6.90	  ±	  4.30	  
	   	  
-­‐3.37,	  1.67	  
	  
0.506	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Symptoms	  of	  DVT	   1	  (20)	   4	  (80)	   3.18	   0.5,	  20.1	   0.761	  
	  
Treatment	  in	  ICU	  
	  	  	  	  	  Central	  Venous	  catheters	  
	  	  	  	  	  	  	  	  	  	  Internal	  Jugular	  
	  	  	  	  	  	  	  	  	  	  Subclavian	  
	  	  	  	  	  	  	  	  	  	  Femoral	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Peripherally	  inserted	  central	  
catheters	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Dialysis	  ports	  
	  	  	  	  	  	  	  	  	  	  Jugular	  
	  	  	  	  	  	  	  	  	  	  Femoral	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Mechanical	  ventilation	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Sedatives	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  	  
	  
	  	  	  	  	  Muscle	  relaxants	  
	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  Vasopressors	  
	  	  	  	  	  	  	  	  	  	  Dopamine	  
	  	  	  	  	  	  	  	  	  	  Adrenaline	  
	  	  	  	  	  	  	  	  	  	  Noradrenaline	  
	  	  	  	  	  	  	  	  	  	  Dobutamine	  
	  	  	  	  	  	  	  	  	  	  Multiple	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Transfusions	  
	  	  	  	  	  	  	  	  	  Packed	  cells	  
	  	  	  	  	  	  	  	  	  Platelets	  
	  	  	  	  	  	  	  	  	  FFP	  
	  	  	  	  	  	  	  	  	  Multiple	  
	  
	  
	  
11	  (9)	  
8	  (13)	  
1	  (20)	  
2	  (4)	  
9	  ±	  3.9	  
	  
1	  (33)	  
	  
10	  
	  
1	  (10)	  
-­‐-­‐-­‐	  
1	  (13)	  
15	  
	  
9	  (7)	  
9.56	  ±	  6.31	  
	  
7	  (6)	  
5	  ±	  2.58	  
	  
	  
	  
8	  (9)	  
-­‐-­‐-­‐	  
3	  (14)	  
2	  (7)	  
-­‐-­‐-­‐	  
3	  (9)	  
4.38	  ±	  2.13	  
	  
2	  (8.0)	  
1	  (13)	  
1	  (25)	  
-­‐-­‐-­‐	  
-­‐-­‐-­‐	  
	  
	  
105	  (91)	  
56	  (87)	  
4	  (80)	  
45	  (96)	  
6.96	  ±	  2.97	  
	  
2	  (67)	  
	  
5.50	  ±	  0.70	  
	  
9	  (90)	  
2	  (100)	  
7	  (87)	  
8.44	  ±	  4.87	  
	  
129	  (93)	  
7.32	  ±	  5.16	  
	  
107	  (94)	  
3.64	  ±	  2.74	  
	  
	  
	  
83	  (91)	  
2	  (100)	  
19	  (86)	  
29	  (93)	  
2	  (100)	  
31	  (91)	  
4.04	  ±	  2.92	  
	  
23	  (92.0)	  
7	  (87)	  
3	  (75)	  
3	  
10	  
	  
	  
6.06	  
3.62	  
3.18	  
0.56	  
	  
	  
5.36	  
	  
	  
	  
1.54	  
	  
1.95	  
	  
	  
0.91	  
	  
	  
0.81	  
	  
	  
	  
	  
1.95	  
	  
2.39	  
0.96	  
	  
1.43	  
	  
	  
1.24	  
1.95	  
4.00	  
	  
	  
0.80,	  45.94	  
1.14,	  11.57	  
0.5,	  20.11	  
0.1,	  2.48	  
0.11,	  3.96	  
	  
0.98,	  29.34	  
	  
-­‐6.5,	  15.5	  
	  
0.22,	  10.81	  
	  
0.28,	  13.33	  
-­‐5.30,	  18.4	  
	  
0.25,	  3.21	  
-­‐1.33,	  5.81	  
	  
0.27,	  2.45	  
-­‐0.75,	  3.48	  
	  
	  
	  
0.61,	  6.27	  
	  
0.7,	  8.16	  
0.22,	  4.17	  
	  
0.40,	  5.00	  
-­‐1.78,	  2.45	  
	  
0.28,	  5.33	  
0.29,	  13.33	  
0.66,	  23.98	  
	  
	  
0.08	  
0.043	  
0.761	  
0.666	  
0.03	  
	  
0.483	  
	  
0.121	  
	  
0.827	  
	  
0.961	  
0.238	  
	  
0.83	  
0.217	  
	  
0.95	  
0.203	  
	  
	  
	  
0.391	  
	  
0.345	  
0.731	  
	  
0.858	  
0.751	  
	  
0.885	  
0.961	  
0.636	  
	  
Laboratory	  investigations	  
	  	  	  	  	  Mean	  PT	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  
	  
	  
13.04	  ±	  2.06	  
15.37	  ±	  2.97	  
	  
	  
	  
14.03	  ±	  6.01	  
13.3	  ±	  3.60	  
	  
	  
	  
	  
	  
	  
	  
	  
-­‐4.77,	  2.80	  
-­‐0.24,	  4.34	  
	  
	  
	  
0.607	  
0.080	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  D7	  	  
	  
	  	  	  	  	  Mean	  INR	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  	  	  	  	  Mean	  APTT	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  	  	  	  	  Mean	  platelet	  counts	  
	  	  	  	  	  	  	  	  	  	  D1	  (Mean	  ,	  SD)	  
	  	  	  	  	  	  	  	  	  	  (Median,	  IQR)	  
	  	  	  	  	  	  	  	  	  	  D3	  (Mean	  ,	  SD)	  
	  	  	  	  	  	  	  	  	  	  (Median,	  IQR)	  
	  	  	  	  	  	  	  	  	  	  D7	  (Mean	  ,	  SD)	  
	  	  	  	  	  	  	  	  	  	  (Median,	  IQR)	  
	  
	  	  	  	  	  	  	  	  	  	  D1	  platelets	  <100000	  
	  	  	  	  	  	  	  	  	  	  D1	  platelets	  >100000	  
	  
	  	  	  	  	  	  	  	  	  	  D1	  platelets	  <180000	  
	  	  	  	  	  	  	  	  	  	  D1	  platelets	  >180000	  
	  
13.48	  ±	  2.71	  
	  
	  
1.184	  ±	  0.18	  
1.39	  ±	  0.26	  
1.22	  ±	  0.23	  
	  
31.93	  ±	  5.76	  
38.23	  ±	  7.69	  
36.52	  ±	  11.96	  
	  
3.37L	  ±	  2.22L	  
3L	  (1.6,	  5.5)	  
2.63L	  ±	  1.97L	  
2.4L	  (1.2,	  4.6)	  
2.17L	  ±	  1.49L	  
1.68L	  (1.2,	  2.8)	  
	  
3	  (4)	  
8	  (8)	  
	  
2	  (5)	  
9	  (7)	  
12.59	  ±	  4.10	  
	  
	  
1.27	  ±	  0.53	  
1.21	  ±	  0.32	  
1.14	  ±	  0.35	  
	  
32.9	  ±	  12.77	  
32.84	  ±	  12.68	  
32.03	  ±	  10.56	  
	  
2.14L	  ±	  1.35L	  
2.08	  L(1.1,3.1)	  
2.25L	  ±	  2.53L	  
1.9L	  (0.8,	  2.9)	  
1.91	  ±	  1.23L	  
1.8L	  (0.93,	  2.6)	  
	  
72	  (96)	  
94	  (92)	  
	  
40	  (95)	  
126	  (93)	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
1.96	  
	  
	  
1.4	  
-­‐1.6,	  3.39	  
	  
	  
-­‐0.41,	  0.24	  
-­‐0.02,	  0.38	  
-­‐0.13,	  0.29	  
	  
-­‐9.03,	  7.08	  
-­‐2.64,	  13.4	  
-­‐2.15,	  11.1	  
	  
0.35,	  2.1	  
	  
-­‐1.15,	  1.91	  
	  
-­‐0.52,	  1.04	  
	  
	  
0.54,	  7.14	  
	  
	  
0.31,	  6.22	  
0.481	  
	  
	  
0.604	  
0.090	  
0.477	  
	  
0.812	  
0.187	  
0.184	  
	  
0.006	  
	  
0.625	  
	  
0.510	  
	  
	  
0.464	  
	  
	  
0.935	  
	  
Thromboprophylaxis	  
	  	  	  	  	  Pharmacological	  
	  	  	  	  	  	  	  	  	  	  Heparin	  
	  	  	  	  	  	  	  	  	  	  Enoxaparin	  
	  	  	  	  	  	  	  	  	  	  Adequate	  dosage	  
	  	  	  	  	  Mechanical	  
	  	  	  	  	  Both	  
	  
	  
12	  (100)	  
9	  (9)	  
	  	  	  9	  (9)	  
	  	  	  -­‐-­‐-­‐	  
	  	  	  9	  (100)	  
3	  (4)	  
-­‐-­‐-­‐	  
	  
168	  (100)	  
95	  (91)	  
	  	  	  95	  (91)	  
	  	  	  5	  
	  	  	  95	  (100)	  
68	  (96)	  
5	  
	  
	  
2.19	  
2.19	  
	  
	  
0.51	  
	  
	  
0.61,	  7.82	  
0.61,	  7.82	  
	  
	  
0.14,	  1.82	  
	  
	  
0.343	  
0.343	  
	  
	  
0.45	  
No	  comparisons	  were	  made	  as	  one	  of	  the	  arms	  either	  had	  complete	  absence	  of	  the	  risk	  
factor,	  or	  the	  occurrence	  was	  equal	  in	  both	  the	  arms.	  
IQR=interquartile	  range,	  SD=standard	  deviation,	  PIC=peripherally	  inserted	  central	  catheters.	  
PT	  and	  APTT	  have	  been	  given	  in	  seconds	  and	  platelets	  in	  lakhs.	  
	  
	  
	  
	  
	  
79	  
	  
INDEPENDENT	  RISK	  FACTORS	  FOR	  THE	  DEVELOPMENT	  OF	  NON	  CATHETER	  
RELATED	  DVT	  IN	  MEDICAL	  ICU	  
	  
 Logistic regression was done for the risk factors which had atleast 10% significance 
(p<0.1) in the bivariate analysis. This included the presence of central venous catheter, age 
more than forty years, day 3 PT and day 1 platelet count. In addition, SOFA score was 
included to adjust for severity of co morbidities.  
In the first model (Table 25), although central venous catheters and age emerged as risk 
factors, they were not statistically significant. This model was of adequate fit and predicted 
22% of the variability. The only variable which was statistically significant was the platelet 
count on day 1. The relative risk for the same was one, implying no risk. Hence, a second 
model (Table 26) was done excluding them, the outcomes of which were not statistically 
significant.  
As platelet counts at day 1 had emerged significant in the first model, despite there 
being no risk per se, categorization of the same was done. A third model was designed, based 
on the second model with the inclusion of platelets counts of more than one lakh at day 1, as 
this was thought to be more clinically relevant (Table 27). Furthermore, as the median value of 
the day 1 platelet count was nearly 1.8 lakhs, it was again categorized based on this value, 
creating the fourth model (table 28). Similar results were observed in these models too, 
wherein, central venous catheters and age had turned up as risk factors, but were not 
statistically significant. 
As none of the factors were independently associated with the development of non 
catheter related DVT, the small event rate was thought to be responsible. A retrospective 
power analysis was done (from model 3), which showed that the power estimated was 52%. 
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Therefore, it was concluded that a larger event rate would have been required to adequately 
power the study. 
Table	  25	  -­‐	  Multivariate	  Analysis-­‐Risk	  factors	  for	  Non	  catheter	  related	  DVT	  in	  MICU–Model	  1	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   3.27	   0.36,	  30.0	   0.29	  
2.	   Age	  >	  40	  yrs	   4.31	   0.49,	  37.49	   0.19	  
3.	   Day	  1	  platelet	  count	   1.00	   1.00,	  1.00	   0.02	  
4.	   Day	  3	  PT	   1.12	   0.97,	  1.29	   0.13	  
5.	   SOFA	   1.05	   0.85,	  1.29	   0.66	  
Nagelkerke	  R	  Square	  =	  0.228,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.264	  (good	  fit)	  
Table	  26	  -­‐	  Multivariate	  Analysis-­‐Risk	  factors	  for	  Non	  catheter	  related	  DVT	  in	  MICU–Model	  2	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   4.04	   0.46,	  35.65	   0.21	  
2.	   Age	  >	  40	  yrs	   5.99	   0.71,	  50.54	   0.10	  
3.	   Day	  3	  PT	   1.10	   0.96,	  1.26	   0.16	  
4.	   SOFA	   0.94	   0.79,	  1.11	   0.45	  
Nagelkerke	  R	  Square	  =	  0.148,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.286	  (good	  fit)	  
Table	  27	  -­‐	  Multivariate	  Analysis-­‐Risk	  factors	  for	  Non	  catheter	  related	  DVT	  in	  MICU–Model	  3	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   4.16	   0.47,	  36.92	   0.20	  
2.	   Age	  >	  40	  yrs	   5.68	   0.66,	  48.49	   0.11	  
3.	   Day	  1	  platelet	  count	  >	  1	  lakh	   1.78	   0.29,	  11.04	   0.53	  
4.	   Day	  3	  PT	   1.1	   0.96,	  1.26	   0.17	  
5.	   SOFA	   0.96	   0.79,	  1.16	   0.69	  
Nagelkerke	  R	  Square	  =	  0.153,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.28	  (good	  fit)	  
Table	  28	  -­‐	  Multivariate	  Analysis-­‐Risk	  factors	  for	  Non	  catheter	  related	  DVT	  in	  MICU–Model	  4	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Central	  Venous	  Catheters	   4.15	   0.47,	  36.82	   0.20	  
2.	   Age	  >	  40	  yrs	   5.82	   0.68,	  49.45	   0.11	  
3.	   Day	  1	  platelet	  count	  >	  1.8	  lakh	   3.06	   0.58,	  16.24	   0.19	  
4.	   Day	  3	  PT	   1.12	   0.97,	  1.28	   0.12	  
5.	   SOFA	   0.99	   0.82,	  1.19	   0.93	  
Nagelkerke	  R	  Square	  =	  0.176,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.55	  (good	  fit)	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RISK	  FACTORS	  FOR	  IN-­‐HOSPITAL	  MORTALITY	  IN	  PATIENTS	  GETTING	  ADMITTED	  
TO	  THE	  MEDICAL	  ICU	  
	  
 The risk factors for in-hospital mortality were studied amongst these patients, in order 
to determine the clinical relevance of these deep venous thrombi. It was intriguing to 
determine if these venous thrombi, which occurred in the patients getting admitted to the 
medical intensive care, despite being on thromboprophylaxis, posed a clinically significant 
threat to the outcomes of these patients. Therefore, risk factor analysis was done in all patients 
included in the study, excluding the discharges against medical advice. The risk factors and the 
presence of DVT were compared between the mortality group (in hospital deaths) and the 
survivor group (discharged alive from the hospital). Bivariate analysis (Table 29) revealed the 
following factors to be the significant predictors of in-hospital mortality for patients getting 
admitted to the medical intensive care facility: 
1) Mechanical Ventilation, 3.83 (1.46, 10.07), p=0.02 
2) Use of Vasopressors, 3.26 (1.78, 5.95), p<0.001 
3) Central Venous Catheters, 2.8 (1.34, 5.85), p=0.003 
4) Use of Sedatives, 2.19 (1.23, 6.32), p=0.006 
5) Transfusions, 1.91 (1.16, 3.12), p=0.03 
6) Mechanic thromboprophylaxis, 1.86 (1.17, 2.95), p=0.01 
7) Age > 40yrs, 1.63 (1.0, 2.67), p=0.06 
8) Pharmacological thromboprophylaxis, 0.54 (0.33, 0.86), p=0.01 
9) SOFA score, (1.46, 4.19), p=0.01 
10)  Day3 PT/INR (0.03, 3.23), p=0.04 
11)  Day3 APTT (1.85, 12.27), p=0.009 
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It was seen that most of the risk factors for in-hospital mortality were surrogate markers of 
severity of illness (necessitating intensive care management), like, the need for mechanical 
ventilation, inotropic supports, central venous catheters, transfusions and SOFA score. It was 
interesting to note that specifically, those on femoral venous catheters (2.3), receiving multiple 
vasopressors (2.8) and multiple transfusions (2.37), seemed to be a higher risk. It was also 
interesting to find that while pharmacological thromboprophylaxis was a significant protective 
factor against in-hospital mortality; mechanical thromboprophylaxis was associated with 
adverse outcomes. This could be attributed to the factors pre-existent in the patient, which 
might preclude the use of pharmacological prophylaxis, like coagulopathy, which could 
indicate an underlying multi-organ dysfunction or a severe sepsis syndrome. The day 3 PT and 
APTT also seemed to play a significant role. 
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Table	  29	  –	  Bivariate	  Analysis	  –	  Risk	  factors	  for	  In-­‐Hospital	  mortality	  in	  patients	  getting	  
admitted	  to	  the	  MICU	  
Risk	  factors	  
(n=200)	  
[19	  DAMA;	  219-­‐19=200]	  
Mortality	  
(n=54)	  
n	  (%)	  
Survivors	  
(n=146)	  
n	  (%)	  
Relative	  
Risk	  	  
95%	  CI	   P	  value	  
	  
Mean	  Age	  (yrs)	  
Age	  >40	  yrs	  
Age	  <40	  yrs	  
	  
	  
48.28±16.36	  
36	  (33.3)	  
18	  (20)	  
	  
42.48±17.07	  
74	  (66.7)	  
72	  (80)	  
	  
	  
1.63	  
	  
0.49,	  11.10	  
1.0,	  2.67	  
	  
0.032	  
0.06	  
	  
Male	  gender	  	  
Female	  gender	  	  
	  
	  
34	  (31)	  
20	  (23)	  
	  
77	  (69)	  
69	  (77)	  
	  
1.36	  
	  
0.84,	  2.11	  
	  
0.257	  
	  
Past	  history	  
	  	  	  	  	  Surgery	  (within	  4	  wks)	  	  
	  	  	  	  	  Trauma	  (within	  4	  wks)	  	  
	  	  	  	  	  Hospitalization	  (>3days)	  
	  	  	  	  	  Central	  catheters	  	  
	  	  	  	  	  NSAID	  use	  	  
	  	  	  	  	  Rheumatic	  /	  autoimmune	  	  
	  
	  
	  
4	  (33)	  
1	  (25)	  
13	  (36)	  
1	  (50)	  
1	  (50)	  
4	  (27)	  
	  
	  
8	  (67)	  
3	  (75)	  
23	  (64)	  
1	  (50)	  
1	  (50)	  
11	  (73)	  
	  
	  
1.25	  
0.92	  
1.44	  
-­‐	  
-­‐	  
0.98	  
	  
	  
0.54,	  2.89	  
0.16,	  5.12	  
0.86,	  2.40	  
	  
	  
0.41,	  2.35	  
	  
	  
0.86	  
0.63	  
0.24	  
	  
	  
0.78	  
	  
Present	  history	  	  
	  	  	  	  	  Congestive	  cardiac	  failure	  	  
	  	  	  	  	  Chronic	  liver	  failure	  	  
	  	  	  	  	  Chronic	  kidney	  disease	  	  
	  	  	  	  	  Malignancy	  	  
	  	  	  	  	  Post	  partum	  	  
	  	  	  	  	  Immobilization	  	  
	  	  	  	  	  Pacemaker	  Insertion	  	  
	  	  	  	  	  Smoking	  	  
	  	  	  	  	  Alcohol	  	  
	  	  	  	  	  Aspirin	  	  
	  	  	  	  	  Clopidogrel	  	  
	  	  	  	  	  Vitamin	  K	  supplements	  	  
	  	  	  	  	  Other	  comorbidities	  	  
	  
	  
	  
2	  (29)	  
2	  (33)	  
3	  (27)	  
1	  (100)	  
3	  (43)	  
3	  (60)	  
-­‐	  
10	  (32)	  
9	  (21)	  
7	  (30)	  
6	  (33)	  
13	  (38)	  
32	  (34)	  
	  
	  
5	  (71)	  
4	  (67)	  
8	  (73)	  
-­‐	  
4	  (57)	  
2	  (40)	  
4	  (100)	  
21	  (68)	  
34	  (79)	  
16	  (70)	  
12	  (67)	  
21	  (62)	  
62	  (66)	  
	  
	  
1.06	  
1.24	  
1.01	  
	  
1.62	  
2.29	  
-­‐	  
1.23	  
0.73	  
1.14	  
1.26	  
1.54	  
1.64	  
	  
	  
0.32,	  3.5	  
0.39,	  3.94	  
0.37,	  2.72	  
	  
0.66,	  3.93	  
1.07,	  4.87	  
	  
0.7,	  2.19	  
0.38,	  1.37	  
0.58,	  2.22	  
0.62,	  2.53	  
0.93,	  2.56	  
1.02,	  2.61	  
	  
	  
0.74	  
0.91	  
0.74	  
	  
0.59	  
0.24	  
	  
0.61	  
0.41	  
0.88	  
0.72	  
0.15	  
0.05	  
	  
SOFA	  score	  at	  admission	  to	  ICU	  
	  
9.25±4.44	  
	  
	  
6.43±3.93	  
	   	  
1.46,	  4.19	  
	  
0.01	  
Symptoms	  of	  DVT	   2	  (33)	   4	  (67)	   1.24	   0.39,	  3.94	   0.91	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Treatment	  in	  ICU	  
	  	  	  	  	  Central	  Venous	  catheters	  
	  	  	  	  	  	  	  	  	  	  Internal	  Jugular	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Subclavian	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Femoral	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  PIC	  catheters	  
	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Dialysis	  ports	  
	  	  	  	  	  	  	  	  	  	  Jugular	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Femoral	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Right	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Left	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Mechanical	  ventilation	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Sedatives	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  	  
	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  Vasopressors	  
	  	  	  	  	  	  	  	  	  	  Dopamine	  
	  	  	  	  	  	  	  	  	  	  Adrenaline	  
	  	  	  	  	  	  	  	  	  	  Noradrenaline	  
	  	  	  	  	  	  	  	  	  	  Dobutamine	  
	  	  	  	  	  	  	  	  	  	  Multiple	  
	  	  	  	  	  	  	  	  	  	  Mean	  duration	  (days)	  
	  
	  	  	  	  	  Transfusions	  
	  	  	  	  	  	  	  	  	  Packed	  cells	  
	  	  	  	  	  	  	  	  	  Whole	  blood	  
	  
	  
47	  (33)	  
18	  (26)	  
17	  (26)	  
1	  (33)	  
-­‐	  
-­‐	  
-­‐	  
29	  (43)	  
27	  (45)	  
2	  (29)	  
7.11±3.57	  
	  
-­‐	  
	  
-­‐	  
	  
	  
3	  (19)	  
1	  (25)	  
-­‐	  
1	  (33)	  
2	  (17)	  
-­‐	  
2	  (33)	  
5.0±2.6	  
	  
50	  (33)	  
8.48±5.04	  
	  
42	  (34)	  
3.93±2.24	  
	  
43	  (39)	  
1	  (25)	  
7	  (32)	  
10	  (29)	  
-­‐	  
25	  (53)	  
4.44±2.78	  
	  
12	  (46)	  
2	  (25)	  
1	  (100)	  
	  
	  
94	  (67)	  
50	  (74)	  
48	  (74)	  
2	  (67)	  
6	  
5	  (100)	  
1	  (100)	  
38	  (57)	  
33	  (55)	  
5	  (71)	  
7.29±2.76	  
	  
1	  (100)	  
	  
1	  (100)	  
5	  
	  
13	  (81)	  
3	  (75)	  
1	  (100)	  
2	  (67)	  
10	  (83)	  
6	  (100)	  
4	  (67)	  
10.0±4.89	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  (67)	  
6.78±4.94	  
	  
81	  (66)	  
3.46±2.48	  
	  
66	  (61)	  
3	  (75)	  
15	  (68)	  
25	  (71)	  
1	  (100)	  
22	  (47)	  
3.64±2.08	  
	  
14	  (54)	  
6	  (75)	  
-­‐	  
	  
	  
2.80	  
0.97	  
0.95	  
1.23	  
	  
	  
	  
2.30	  
2.33	  
1.06	  
	  
	  
	  
	  
	  
	  
	  
0.67	  
0.92	  
	  
1.23	  
0.60	  
-­‐	  
1.24	  
	  
	  
3.83	  
	  
	  
2.19	  
	  
	  
3.26	  
0.92	  
1.20	  
1.07	  
-­‐	  
2.8	  
	  
	  
1.91	  
0.92	  
-­‐	  
	  
	  
1.34,	  5.85	  
0.59,	  1.57	  
0.58,	  1.56	  
0.24,	  6.24	  
	  
	  
	  
1.47,	  3.6	  
1.5,	  3.62	  
0.32,	  3.5	  
-­‐1.26,	  0.89	  
	  
	  
	  
	  
	  
	  
0.23,	  1.92	  
0.16,	  5.12	  
	  
0.24,	  6.24	  
0.16,	  2.18	  
	  
0.39,	  3.94	  
-­‐11.38,	  1.38	  
	  
1.46,	  10.07	  
-­‐0.03,	  3.39	  
	  
1.23,	  6.32	  
-­‐0.43,	  1.37	  
	  
1.78,	  5.95	  
0.16,	  5.1	  
0.62,	  2.32	  
0.51,	  1.91	  
	  
1.83,	  4.28	  
-­‐0.12,	  1.73	  
	  
1.16,	  3.12	  
0.27,	  3.13	  
	  
	  
	  
0.003	  
0.96	  
0.98	  
0.68	  
	  
	  
	  
<0.001	  
<0.001	  
0.73	  
0.75	  
	  
	  
	  
	  
	  
	  
0.63	  
0.63	  
	  
0.68	  
0.61	  
	  
0.91	  
0.115	  
	  
0.002	  
0.050	  
	  
0.006	  
0.30	  
	  
<0.001	  
0.63	  
0.77	  
0.98	  
	  
<0.001	  
0.087	  
	  
0.03	  
0.78	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No	  comparisons	  were	  made	  as	  one	  of	  the	  arms	  either	  had	  complete	  absence	  of	  the	  risk	  
factor,	  or	  the	  occurrence	  was	  equal	  in	  both	  the	  arms.	  
IQR=interquartile	  range,	  SD=standard	  deviation,	  PIC=peripherally	  inserted	  central	  catheters.	  
PT	  and	  APTT	  have	  been	  given	  in	  seconds	  and	  platelets	  in	  lakhs.	  
	  	  	  	  	  	  	  	  	  Platelets	  
	  	  	  	  	  	  	  	  	  FFP	  
	  	  	  	  	  	  	  	  	  Multiple	  
2	  (50)	  
1	  (33)	  
6	  (60)	  
2	  (50)	  
2	  (67)	  
4	  (40)	  
-­‐	  
1.23	  
2.37	  
	  
0.24,	  6.24	  
1.35,	  4.16	  
	  
0.68	  
0.04	  
	  
Laboratory	  investigations	  
	  	  	  	  	  Mean	  PT	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  	  	  	  	  Mean	  INR	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  	  	  	  	  Mean	  APTT	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  	  	  	  	  Mean	  platelet	  counts	  
	  	  	  	  	  	  	  	  	  	  D1	  	  
	  	  	  	  	  	  	  	  	  	  D3	  	  
	  	  	  	  	  	  	  	  	  	  D7	  	  
	  
	  
	  
	  
16.10±13.07	  
14.94±5.0	  
13.63±7.12	  
	  
1.47±1.28	  
1.35±0.45	  
1.23±0.60	  
	  
36.11±16.29	  
38.12±18.24	  
32.23±8.12	  
	  
1.91	  ±	  1.64	  
1.88	  ±	  2.59	  
1.72	  ±	  1.44	  
	  
	  
	  
14.32±7.38	  
13.3±4.99	  
12.2±1.73	  
	  
1.21±0.62	  
1.20±0.45	  
1.11±0.15	  
	  
33.02±12.89	  
31.06±8.31	  
32.63±12.44	  
	  
2.17	  ±	  1.36	  
2.24	  ±	  2.33	  
1.93	  ±	  1.11	  
	  
	  
	  
	  
	  
	  
	  
	  
-­‐1.31,	  4.87	  
0.03,	  3.23	  
-­‐0.98,	  3.80	  
	  
-­‐0.10,	  0.46	  
0.003,	  0.29	  
-­‐0.09,	  0.32	  
	  
-­‐1.58,	  7.76	  
1.85,	  12.27	  
-­‐4.8,	  4.01	  
	  
-­‐0.71,0.20	  
-­‐1.11,	  0.40	  
-­‐0.66,	  0.22	  
	  
	  
	  
0.25	  
0.045	  
0.24	  
	  
0.21	  
0.04	  
0.26	  
	  
0.19	  
0.009	  
0.857	  
	  
0.27	  
0.35	  
0.33	  
	  
Thromboprophylaxis	  
	  	  	  	  	  Pharmacological	  
	  	  	  	  	  	  	  	  	  	  Heparin	  
	  	  	  	  	  	  	  	  	  	  Enoxaparin	  
	  	  	  	  	  Mechanical	  
	  	  	  	  	  Both*	  
	  
	  
54	  (27)	  
22	  (20)	  
19	  (18)	  	  
3	  (50)	  
31	  (37)	  
1	  (25)	  
	  
146	  (73)	  
90	  (80)	  
87	  (82)	  
3	  (50)	  
53	  (63)	  
3	  (75)	  
	  
	  
0.54	  
0.48	  
-­‐	  
1.86	  
0.92	  
	  
	  
0.33,	  0.86	  
0.29,	  0.78	  
	  
1.17,	  2.95	  
0.16,	  5.12	  
	  
	  
0.01	  
0.003	  
	  
0.01	  
0.63	  
Duration	  of	  ICU	  stay	   8.44	  ±	  5.5	   6.83	  ±	  5.35	   	   -­‐0.08,	  3.30	   0.063	  
Duration	  of	  Hospital	  stay	   15.39	  ±	  
15.15	  
14.65	  ±	  9.35	   	   -­‐2.78,	  4.25	   0.69	  
Mean	  time	  of	  DVT	  development	  
from	  admission	  into	  MICU	  
3.14	  ±	  2.28	   2.75	  ±	  0.67	   	   -­‐0.81,	  1.6	   0.515	  
Mean	  time	  of	  DVT	  development	  
from	  admission	  into	  Hospital	  
7.71	  ±	  9.16	   5.31	  ±	  5.31	   	   -­‐1.84,	  6.79	   0.255	  
Presence	  of	  DVT	   14	  (30)	   32	  (70)	   1.17	   0.70,	  1.95	   0.68	  
ICU	  Incident	  DVT	  (D3	  +	  D7)	   9	  (29)	   22	  (71)	   1.09	   0.59,	  1.99	   0.95	  
D1	  DVT	   5	  (33)	   10	  (67)	   1.25	   0.59,	  2.67	   0.78	  
Non	  Catheter	  related	  DVT	  	   3	  (25)	   9	  (75)	   0.92	   0.33,	  2.52	   0.86	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The presence of DVT was also compared between the two groups to look for any 
influence exerted by the former on mortality. Nearly 30% of those who had developed a DVT 
in the medical ICU had unfavourable hospital outcomes. The presence of DVT per se appeared 
to confer risk (1.17), but this was not statistically significant. Amongst the DVTs, the day 1 
DVTs appeared to confer higher risk (1.25), than the incident DVTs (1.09); however the 
differences were not statistically significant.  
INDEPENDENT	  RISK	  FACTORS	  FOR	  IN-­‐HOSPITAL	  MORTALITY	  IN	  THE	  MEDICAL	  
INTENSIVE	  CARE	  UNIT	  
	  
It was seen in the multivariate analysis that only mechanical ventilation and day 3 
APTT turned out as independent predictors of in-hospital mortality in patients getting admitted 
to the medical intensive care. This model was of good fit and could predict 30% of the 
variability. 
 
Table	  	  30	  -­‐	  Multivariate	  Analysis	  -­‐	  Risk	  factors	  for	  In-­‐Hospital	  mortality	  in	  patients	  getting	  
admitted	  to	  the	  MICU	  
	  
S.No.	   Risk	  Factors	   Relative	  Risk	   95%	  CI	   P	  Value	  
1.	   Mechanical	  Ventilation	   6.31	   1.22,	  32.58	   0.028	  
2.	   Vasopressors	   2.28	   0.72,	  7.2	   0.16	  
3.	   Transfusions	   2.18	   0.75,	  6.38	   0.15	  
4.	   Sedatives	   1.47	   0.54,	  4.02	   0.45	  
5.	   Central	  Venous	  Catheters	   1.32	   0.36,	  4.84	   0.68	  
6.	   Age	  >40	  yrs	   1.13	   0.51,	  2.54	   0.77	  
7.	   SOFA	  score	   1.07	   0.97,	  1.19	   0.18	  
8.	   Day	  3	  APTT	   1.05	   1.002,	  1.092	   0.04	  
9.	   Day	  3	  INR	   0.54	   0.19,	  1.46	   0.22	  
10.	  	   Pharmacological	  Thromboprophylaxis	   0.58	   0.04,	  7.75	   0.68	  
11.	   Mechanical	  Thromboprophylaxis	   0.65	   0.05,	  9.1	   0.75	  
Nagelkerke	  R	  Square	  =	  0.301,	  Hosmer-­‐Lemeshow	  test	  value	  =	  0.132	  (good	  fit)	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PROBABILITY	  OF	  DVT	  FREE	  SURVIVAL	  IN	  THE	  MEDICAL	  ICU	  
	  
 It was seen that the overall probability of DVT free survival in the medical ICU came 
down as the duration of the ICU stay increased, with the steepest drop being observed at 
around day 3 of ICU stay (Figure 19). This was consistent with the mean duration of ICU stay 
at DVT development, which was determined to be 3.8 ± 1.6 days. Similar DVT free survival 
curves were drawn for age, gender and other ICU related exposure factors (Figures 20-27). 
Statistically significant differences were observed with age (p=0.02), central venous catheters 
(p<0.001), dialysis ports (p=0.008) and vasopressors (p=0.021). It was seen that the 
probability of DVT free survival in the medical ICU was lesser for those above the age of forty 
years (Figure 20) and those on central venous catheters (Figure 22), dialysis ports (Figure 23) 
or vasopressors (Figure 24).  
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Figure 19 - Probability of DVT free survival in the MICU 
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Figure 20 – Effect of Age on the Probability of DVT free survival in the MICU (p=0.02) 
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Figure 21 – Effect of Gender on the Probability of DVT free survival in the MICU 
(p=0.49) 
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Figure 22 – Effect of Central Venous Catheters on the Probability of DVT free survival 
in the MICU (p<0.001) 
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Figure 23 – Effect of Dialysis ports on the Probability of DVT free survival in the MICU 
(p=0.008) 
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Figure 24 – Effect of Vasopressors on the Probability of DVT free survival in the MICU 
(p=0.021) 
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Figure 25 – Effect of Mechanical Ventilation on the Probability of DVT free survival in 
the MICU (p=0.345) 
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Figure 26 – Effect of Transfusions on the Probability of DVT free survival in the MICU 
(p=0.639) 
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Figure 27 – Effect of Vitamin K on the Probability of DVT free survival in the MICU 
(p=0.99) 
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DISCUSSION	  
 
INCIDENCE	  OF	  DVT	  IN	  THE	  MEDICAL	  INTENSIVE	  CARE	  UNIT	  
 
 In our medical intensive care unit, despite adequate thromboprophylaxis, the incidence of DVT 
was found to be 17.2% (12.0, 22.3) during the first seven days of ICU admission. The mean duration 
of ICU stay had been nearly a week in this group. However, two thirds of these DVTs were catheter 
related (related to and therefore provoked by the insertion of a central venous catheter or a dialysis 
port) and the incidence of non-catheter related DVTs was only 5.9% (2.6, 9.1), which was considered 
to be clinically significant. Nearly three fourths were proximal lower limb DVTs, (only a small 
proportion were distal lower limb DVTs in our study) while the remaining were contributed by upper 
limb DVTs (all jugular).   
Overall, nearly half the DVTs had resolved spontaneously, over the subsequent 3 days, and 
nearly three fourths had resolved by a week. Less than 10% (8.6%) of these patients had been 
discharged with a diagnosis of DVT, after being started on oral anticoagulation therapy for the same. 
This contributed to 1.5% of the study population, who had developed clinically significant and 
proximally propagating DVTs during their hospital stay, thus, necessitating the initiation of oral 
anticoagulation.  
The natural course of catheter related DVTs was slightly more favourable than the non catheter 
related ones. In the former, spontaneous resolution in 3 and 7 days from onset, had been observed in 
50% and 80% respectively, while in the latter, the same had been seen in one thirds and two thirds 
respectively. Therefore, the catheter related ones appeared to show faster resolution.  
The mean duration of hospital stay was found to be longer (with the median duration being 
nearly twice as long) in patients with DVT. Although, it would be premature to conclude that this 
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effect was solely attributable to the presence of DVTs, two reasons were initially hypothesized for this 
association. Firstly, the patients who had developed DVT could have had more severe illness, thereby, 
requiring a longer duration of hospitalization, largely owing to the overall severity of illness, which in 
itself could have also predisposed to the presence of DVT also. Secondly, this could be due to the 
presence of the DVT per se. However, there was no significant difference between the SOFA scores 
(which was the surrogate marker for severity of illness) of the DVT and the non DVT groups, and 
hence no difference in the severity of illness between the two groups, thereby implying that the 
presence of DVT per se is the more biologically plausible explanation for the longer duration of 
hospitalization.  
The proportion of sudden deaths was more in the DVT group, but this observation was not 
statistically significant. There was no documented pulmonary embolism in our study. There was no 
significant difference in the secondary outcomes between the non catheter related and the catheter 
related DVTs. The mean duration of hospitalization (29.17 vs. 19.77) and the mean duration of 
hospital stay at the time of development of DVT (9.33 vs. 6.13) was found to be apparently longer in 
the non catheter related group, although there was no statistical significance. Therefore, in contrast to 
the catheter related DVTs which occurred earlier, the non catheter related DVTs had a tendency to 
occur with a longer period of hospital stay.   
The probability of DVT free survival in the medical ICU within the first week, varied 
inversely with the duration of ICU stay, with the steepest drop being observed at day 3. Therefore, it 
was interesting to observe that while probability of acquiring a DVT increased with the duration of 
ICU stay, the presence of DVT, in turn, increased the duration of hospitalization. 
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RISK	  FACTORS	  FOR	  DVT	  IN	  THE	  MEDICAL	  INTENSIVE	  CARE	  UNIT	  
	  
The risk factors significantly associated with the development of DVT in the MICU were 
determined to be elderly age (>40 yrs), presence of central venous catheters (especially femoral), 
administration of vasopressors and the day 3 PT/INR. However, central venous catheters were found 
to be independently associated with the development DVT in the medical ICU. Age and day 3 INR 
were also found to confer risk, but did not exhibit statistical significance. As a large number of DVTs, 
encountered in our study (nearly two thirds) had been catheter related, the presence of central venous 
catheters was thought to overshadow the other risk factors in our analysis, Therefore, risk factor 
analysis for the non catheter related DVTs was done, as these DVTs were considered to be 
unprovoked and hence the risk factors implicated in the development of the same were thought to be 
truly reflective of the interplay of the factors involved in the Virchow’s triad.  
The risk factors significantly associated with the development of non catheter related DVTs in 
the medical ICU included age (>40yrs), central venous catheters (especially jugular), day 3 PT and 
day 1 platelet counts. The occurrence of risk factors was similar to that seen with the overall DVTs. 
However, none of them were found to be independently associated with the development of non 
catheter  related DVTs in the medical ICU. This was largely attributed to the small event rate (12 vs. 
168).  Therefore, it was seen that the presence of central venous catheters and older age were 
important risk factors in the medical intensive care setting for the development of DVT (irrespective 
of its association with a central venous catheter).  
Older age (more than forty years), the presence of central venous catheters or dialysis ports 
and administration of vasopressors were found to reduce the probability of DVT free survival in the 
Medical Intensive Care Unit.  
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RISK	  FACTORS	  FOR	  MORTALITY	  IN	  THE	  MEDICAL	  INTENSIVE	  CARE	  UNIT	  
 
The clinical significance of the DVTs observed in our study was not known.  
Only 1.5% of the patients studied (8.6% of patients who had developed DVT in the MICU) 
had been started on anticoagulation for DVT. It was presumed that the DVTs in the remaining patients 
had resolved before discharge.  
The overall mortality rate in this study was 24.7, with 25.7% in the DVT group and 23.8% in 
the non DVT group, with an absolute risk increase of 1.9%; however this observation was not 
statistically significant.   
Therefore, to determine the influence of deep venous thrombosis on the in-hospital mortality 
of patients getting admitted to the medical intensive care unit, risk factor analysis was done. The 
presence of DVT (overall/incident/non catheter related) did not appear to affect the in-hospital 
mortality of patients. The presence of DVT appeared to confer a relative risk of 1.17 (0.7, 1.95) on the 
in-hospital mortality, but this was not statistically significant. Larger studies are required to 
understand the clinical significance of these DVTs. The risk factors which were independently 
associated with in-hospital mortality of patients included mechanical ventilation and APTT (day 3). 
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REGIONAL	  RELEVANCE	  -­‐	  COMPARISON	  WITH	  INDIAN	  DATA	  
	  
 A retrospective study was done in our hospital, a few years ago, to determine the incidence 
of DVT. This study included all hospitalized patients who had been diagnosed with DVT between 
1996 and 2005. The incidence was estimated to be 17.46 per 10,000 hospital admissions, of which 
the large majority (93%) were lower limb DVTs (of which two thirds were proximal). However, as 
this was a retrospective study, details regarding the extent, adequacy and type of 
thromboprophylaxis was not known.(21) 
 Although, it was thought earlier that the risk for DVT was higher among surgical than 
medical patients, one of the studies from India have shown that medical patients have a higher risk 
of venous thromboembolism as compared to surgical patients (6.48 vs. 5.0).(32) This is largely 
attributable to the dynamic interplay between the three factors of the Virchow’s triad, which is more 
commonly seen in the former group.  
A study from the All Indian Institute of Medical Sciences showed that the incidence of DVT 
among hospitalized patients in the general medical wards and intensive care unit was 3%. This was a 
prospective study used the ultrasound Doppler to detect DVT, similar to our study protocol. 
Screening ultrasound scans were done within the first few days of admission and before discharge. 
All the DVTs encountered in this study were proximal lower limb DVTs and all were asymptomatic. 
This observation was similar to our study, wherein, most of our patients with DVT were 
asymptomatic (94.3%). However, in contrast to our study, none of the patients were on 
thromboprophylaxis; which was surprising, given the low incidence quoted by this study.(9) 
However, it is to note that this study was done only in patients with limited mobility.  
 Another study from the same institute showed that the clinical signs and symptoms of DVT 
were present in 25.8% of patients in the medical wards and medical intensive care units. This study 
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also showed that although 75% of patients had been at high risk for developing DVT at the time of 
admission into the medical wards or intensive care units, only 12.5% had been on 
thromboprophylaxis.(8) This again reflects the poor utilization of thromboprophylaxis by Indian 
hospitals.  
A study done amongst geriatric patients admitted to the general medical wards and medical 
intensive care unit, in a hospital in Mumbai, showed that although 13.5% of patients had incident 
DVT as detected by the ultrasound Doppler, only 2.7% were clinically evident. In this study also, 
the thromboprophylaxis coverage had been incomplete. Amongst patients admitted to the intensive 
care unit, only 42% were on thromboprophylaxis. (22)   
A study done in a hospital in Uttar Pradesh looked at the efficacy of thromboprophylaxis 
among a small group of patients admitted to the medical and surgical intensive care units. This was 
a randomized controlled trial, with two thirds being on thromboprophylaxis, and one thirds off the 
same.  The overall incidence of DVT was 13.8% with the incidence of DVT amongst those on and 
off thromboprophylaxis being  8.3% and 25% respectively. This study shows a relative risk 
reduction of 66.8% in the occurrence of DVT reflecting the efficacy of thromboprophylaxis. This 
difference was however not statistically significant due to the small sample size studied.(51) 
A prospective study from Chennai, done among patients admitted to the intensive care unit, 
showed that the incidence of DVT was 6.6% in the absence of thromboprophylaxis. The mean 
duration of stay was 4 weeks and all patients underwent screening ultrasound Doppler at 1-2 weeks 
of admission into the ICU. There were no pulmonary emboli encountered by this study.(52) This 
was surprising as the incidence rate was low despite absence of thromboprophylaxis. However, in 
this study, only a single screening ultrasound Doppler scan was done. Studies have shown that 
periodic surveillance with ultrasound screening increases the detection of DVT in the medical ICU 
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as most of the patients are asymptomatic. It was speculated that more frequent screening could have 
probably increased the yield in this study.  
On comparing our study with the afore-mentioned Indian studies, the following points were 
evident: 
1) There is no data from India on DVT exclusively in the medical intensive care unit. Two of the 
above studies have been done in medical wards and intensive care units, and two in medical and 
surgical intensive care units, and therefore, the interplay of risk factors indigenous to the medical 
intensive care setting may have been diluted. Therefore, they may not be truly reflective of the risk 
for development of DVT as imposed by the medical intensive care unit and the interventions, unique 
to the same.  
2) Although, the current ACCP 2012 guidelines, clearly state that all critically ill patients, need to be 
considered at high risk for development of DVT and hence be started on some form of 
thromboprophylaxis; it was seen that this was not being followed by most Indian hospitals and 
intensive care units. Therefore, the risk for DVT for a patient admitted to the medical intensive care 
unit, while on thromboprophylaxis as per protocol, was still largely unknown. 
3) Most of these studies have looked into the development of proximal lower limb DVTs, while 
ignoring the presence of upper extremity thrombi.  
4) The course of the DVTs encountered in most of these studies and the therapeutic interventions 
have not been clearly defined. Therefore, the need for initiation of anticoagulation in these patients 
with ICU-acquired DVT is not known.  
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GLOBAL	  SIGNIFICANCE	  -­‐	  COMPARISON	  WITH	  GLOBAL	  DATA	  	  
 
 A group in Boston, had published their study in 1995, which bore close resemblance to 
our study, in terms of the study population and the methods used in the diagnosis of DVT. This was 
one of the few studies which had looked at the occurrence of DVT in the critically ill medical patients. 
The study population included patients from the medical intensive care unit, similar to our setting. The 
incidence of DVT was 33% (1), which was very high in contrast to the 17.2% incidence in our study. 
This difference could be attributed to the fact that this study was conducted at a point in time, when 
thromboprophylaxis had not become part of standard care in the medical intensive care setting. The 
thromboprophylaxis coverage in this study was 61%, as compared to our study where there was 100% 
coverage.   
A Chinese study, done nearly a decade later, reported the incidence of DVT to be 19% in the 
intensive care setting in the absence of thromboprophylaxis.(33) This was close to our estimate of 
17.2%, despite 100% thromboprophylaxis. However, it would be premature to conclude that 
thromboprophylaxis does not impact the development of DVT. In our study, the incidence of the more 
clinically relevant non-catheter related DVTs was only 5.9% in contrast to the former.  
A study from Beijing determined the incidence of DVT at 15.1%, which was also close to our 
estimate of the same. However, the institution of thromboprophylaxis in this study and the extent of 
the same is not very clear.(35) It was seen in a study from Thailand that the incidence of DVT was 
8.82% although, adherence to thromboprophylaxis was not complete in this study too.(37) A 
retrospective study done recently in Iran estimated the incidence of DVT to be much lower, at 5.2%. 
The extent of thromboprophylaxis coverage in this study is also not clear.(38)  
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A Canadian study in the medical and surgical intensive care unit, showed a relatively low 
incidence of DVT, similar to the Iranian study (5.4%), with two thirds being covered with 
thromboprophylaxis. However, this low number could be attributed to 2 reasons. Firstly, there was no 
regular surveillance for the development of DVT and secondly, ultrasound was used to diagnosed 
DVT only in those with a high index of clinical suspicion.(26)  Our study has shown that the majority 
of the DVTs in the medical intensive care setting were asymptomatic; and hence screening only those 
symptomatic for DVT creates a large potential to miss the  asymptomatic DVTs which could have 
occurred.  
 
Therefore, the afore mentioned studies show that the incidence of DVT is highly variable in 
the medical intensive care setting, ranging from 5 to 33% across the globe. This variability is probably 
directly attributable to the absence of standard protocols and hence wide differences in the 
thromboprophylaxis administered (both extent and type) and the periodic ultrasound surveillance. 
 Even in the global scenario, there are only a few DVT studies which have been done in the 
medical intensive care unit, with patients on thromboprophylaxis.   
It was seen in a study from Los Angeles, that the incidence of DVT amongst critically ill 
trauma patients was 13%, with adequate (98.5%) thromboprophylaxis.(53) This was also surprisingly 
close to our estimate, given that the study was done in a higher risk group (trauma patients). This 
shows that the differences which were earlier thought to exist between surgical and medical patients; 
and between the west and India, in the risk for development of DVT, are no longer applicable and the 
risks are probably similar across all hospitalized patients. A study from Massachusetts, showed that 
the incidence of proximal lower limb DVT was 12% with 92% thromboprophylaxis coverage.(40)  
The estimates from these two studies are close to our estimates.  
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Surprisingly, another study from the USA, showed that the incidence of DVT was 23.6% 
among the MICU patients with prolonged mechanical ventilation (>7days), with all of them being on 
thromboprophylaxis. This was quite strange as this study quotes one of the highest incidences of DVT 
while on thromboprophylaxis (even higher than in patients not on thromboprophylaxis).(39) 
 
Our study showed that the incidence of DVT in the MICU was 17.2% with 100% 
thromboprophylaxis coverage (56% on pharmacological, 42% on mechanical and 2% on both). The 
following reasons could explain the higher incidence of DVT, encountered in our study despite 
thromboprophylaxis, as compared with some of the above studies.  
1) Transient DVTs (Vanishing thrombi):  
Although, this incidence of DVT could be considered high, while on thromboprophylaxis, it 
was seen that nearly three fourths of these DVTs were transient and resolved within a week (with half 
resolving over 3 days). Also, two thirds were catheter related and were found to have a more 
favourable course with faster resolution. Our frequent and regular ultrasound surveillance within the 
first week of ICU stay, helped us to define the natural course of the DVTs developing in the medical 
ICU. This reflects the subtle interplay of the pro coagulant and anti coagulant mechanisms, which is 
heightened in the intensive care units.  
2) Catheter related thrombi: 
 The catheter related DVTs contributed to two thirds of the incident DVTs in the MICU. The 
incidence of the non catheter related DVTs was found to be 5.9%. These DVTs were thought to be 
more clinically significant and reflective of the true imbalances in the Virchow’s triad, caused by the 
interventions in the intensive care setting; as the former were thought to be provoked by the presence 
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of a catheter which causes direct endothelial injury and thereby directly activating the procoagulant 
cascade.  
3) Inclusion of the upper extremity thrombi: 
 While most of the studies cited above have described only the presence of proximal lower limb 
DVT,  our estimates could be higher due to inclusion of the upper extremity thrombi. The occurrence 
of venous thrombi in both, upper and lower limbs, were thought to be more reflective of the 
pathophysiological mechanisms involved. As central venous catheters are being widely used in the 
intensive care units, which have been implicated as risk factors for the former, it was deemed prudent 
to include the upper limb thromboses also in our study.(54) Also, the complications of pulmonary 
embolism and thromboembolic pulmonary hypertension, which have been classically seen with 
proximal lower limb DVTs, are found to occur in patients with upper extremity thrombi as well.(5,42)  
 
The PROTECT trial showed that despite 100% pharmacological thromboprophylaxis, the 
incidence of proximal lower limb DVT was 5.4% .(41) The incidence of proximal lower limb DVT in 
our study was 11.8%. It should also be remembered that, while all the patients in the PROTECT trial 
were on pharmacological thromboprophylaxis, only 58% were on the same in our study. The 
remaining had contraindications to pharmacological prophylaxis and therefore, had been on 
mechanical thromboprophylaxis. The incidence of non leg DVT was 2.2%(42) in the former, while it 
was 3.9% in our study. The Boston study(1) had also shown that the majority of DVTs encountered 
were from the proximal lower limb, and nearly two thirds were associated with the presence of a 
central venous catheter; which was similar to the observations in our study. Our upper extremity 
thrombi were contributed solely by the jugular involvement. A similar observation was also seen in 
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another study where the large majority of upper extremity thrombi were attributed to the internal 
jugular.(5) 
70% of the DVTs encountered in the Boston study were detected within the first 5 days of ICU 
stay.(1) The Chinese study(33) showed that most of the DVTs in the intensive care setting occurred at 
day 3, similar to our observations. In our study, it was seen that the probability of DVT free survival 
in the medical intensive care unit decreased with a longer duration of MICU stay, with the steepest 
drop being observed at day 3 of ICU stay.  
The Chinese  study also showed that a large number of DVTs encountered in the medical ICU 
were asymptomatic, with only 27% being symptomatic.(33) This concept of asymptomatic DVTs was 
further established by an Indian study where all the DVTs had been asymptomatic.(9) In our study, it 
was seen that only 5.7% of the DVTs observed in the MICU were symptomatic.  
The catheter related DVTs contributed to 40.5% of the incident proximal lower limb DVTs 
and 51% of the non leg DVT in the PROTECT trial.(41,42) The frequency of catheter related thrombi 
were higher in our study, with them contributing 64.7% of the proximal lower limb DVTs and 80% of 
the upper extremity DVTs.  
In the Boston study, it was seen that 21% of patients with DVT required therapeutic 
intervention (in the form of insertion of IVC filters in 9% and initiation of oral anticoagulation in 
12%) (1), in contrast to our study, where only 8.5% (1.5% of the entire study population) required 
therapy in the form of initiation of oral anticoagulation.  In contrast, the Chinese study had shown that 
40% of patients with DVT required initiation of anticoagulation therapy.(33) 
It was seen in the Chinese study(33) that the mortality in the DVT group and the non DVT 
group was 33 vs. 28% as compared to our study where the same was 25.7% vs. 23.8%. This difference 
was smaller in our study and hence not statistically significant. A few studies have shown that the 
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presence of DVT increases the duration of ICU stay and hospitalization.(41,42,53) Similar trends 
were also observed in our study. The difference in the length of hospital stay was statistically 
significant with the duration of hospitalization in the DVT group being nearly 10 days more than that 
in the non DVT group.  
 
Clinically important DVTs were defined as those that were likely cause short term or long term 
morbidity or mortality, in contrast to those that were devoid of clinically significant consequences. A 
survey done among intensivists, revealed three patient factors and three sonological factors which, 
when present, increased the likelihood of a clinically important DVT. The former were leg symptoms, 
clinical suspicion of pulmonary embolism and poor cardiopulmonary reserve as a result of co-morbid 
conditions. The latter included proximal site, large size and total occlusion of the venous lumen by the 
thrombus.(55) In our study, the frequency of patient factors and sonological factors were as follows:  
Patient Factors: 
1) Leg Symptoms: They were seen in 10 patients in the overall study population, of which 
only 2 developed proximal lower limb DVT. Although the incidence of symptomatic DVT 
amongst those with leg symptoms was 20%, the same among the entire study population, was 
very low, at nearly 1%. Therefore, only 1% of patients getting admitted to the medical ICU 
developed symptomatic DVT.  
2) Clinical suspicion of pulmonary embolism: Although there were no cases of confirmed 
pulmonary embolism in our study, there were 9 sudden deaths, one third of which happened in 
the DVT group. Among these sudden deaths, there was a clinical suspicion of pulmonary 
embolism in one patient (1/203=0.05%), who had femoral and jugular thromboses.  
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3) Poor cardiopulmonary reserve: As our study was conducted in a medical intensive care unit, 
most of the patients had poor cardiopulmonary reserve, given the overall requirement of 
mechanical ventilation and vasopressors being 75% and 54% respectively.  
Sonological Factors: 
1) Proximal site : This was seen among those with femoral and jugular thrombi. The incidence 
of proximal deep venous thrombosis was 16.7% in our medical ICU.  
2) Totally occlusive thrombi: The incidence of totally occlusive thrombi or DVTs causing 
complete thrombosis was 4.9% in our medical ICU.  
Therefore, considering the above attributes, although the incidence of DVT in MICU was 
17.2% in our study (with that of non catheter related DVTs being 5.9%), not all satisfied the above 
criteria for clinically important DVT. Also, the incidence of DVTs requiring initiation of oral 
anticoagulation at discharge was only 1.5%. This implies a favourable course with standard 
thromboprophylaxis, with most of the ICU acquired DVTs resolving spontaneously, especially the 
catheter related ones.  
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COMPARISON	  OF	  RISK	  FACTORS	  FOR	  DEVELOPMENT	  OF	  DVT	  IN	  MICU	  
 
 A retrospective study done in our hospital amongst all hospitalized patients with a diagnosis of 
DVT, determined malignancy and surgery to be the two most important risk factors. While this is 
applicable to most surgical patients, they cannot be directly applied to medically ill patients, especially 
in the criticare units, as the risk factors endogenous to the intensive care setting are unique.(21) 
A study done in Mumbai, in the medical and surgical intensive care unit showed that the risk 
factors implicated in the development of DVT in the critically ill were older age, prolonged bed rest 
(among medically ill patients), surgery and central venous catheters (among surgical patients). (32) 
These observations were similar to those made in our study, wherein, the important risk factors 
recognized in the development of DVT in the medical ICU, irrespective of whether they are catheter 
associated or not, included central venous catheters, older age, vasopressors and day 3 INR, of which 
only the presence of central venous catheter was independently associated.  
 In the Boston and the Chinese studies (with inadequate thromboprophylaxis), the risk factors 
for development of DVT in the medical intensive care setting were studied. None of the factors 
traditionally implicated in the development of DVT in the intensive care setting was identified by 
these studies. This was probably attributable to their small study population.(1,33) 
The Beijing study, which was largely done in the emergency and the respiratory intensive care 
setting had identified renal failure, history of surgery and d-dimer as risk factors for development of 
DVT in the ICU.(35)  
The Canadian study done in the medical and surgical intensive care setting had identified 
femoral venous catheters, mechanical ventilation, sedatives and paralytic agents as risk factors, similar 
to our study which had primarily picked up factors endogenous to the intensive care unit, in the form 
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of central venous catheters and vasopressors as ones conferring maximum risk of DVT to these 
patients. Only thromboprophylaxis and warfarin were found to be protective against the development 
of DVT in this study. However, this study included DVTs occurring even prior to the admission in the 
intensive care unit and hence the risk factors may not be strictly indigenous to the intensive care 
setting.(26)  
The Thailand study done exclusively in patients admitted to the medical intensive care unit 
identified the presence of older  age, central venous catheters, female gender and renal replacement 
therapy to be the risk factors associated with the development of DVT. This was similar to the results 
of our study which had also identified central venous catheters to be independently associated with 
DVT development in the medical ICU.(37)  
A study done in Boston, showed that the strongest predictor of upper extremity catheter related 
DVT was the presence of a central venous catheter, while the predictors of non catheter associated 
DVTs included longer hospitalization, smoking and lean body habitus.(54)  
Therefore, the common risk factors which echoed through most of the afore mentioned studies, 
thereby implying its strong association with the development of DVT in the MICU include the presence 
of central venous catheters and older age of the patient. The identification of these risk factors has 
several implications in the medical intensive care unit. As the presence of central venous catheters 
emerged as the sole independent risk factor for the development of DVT in the intensive care setting, 
they should be appropriately used with discretion. The duration of the central venous catheters was 
also found to influence the development of DVT. Therefore, the removal of central venous catheters 
needs to be considered at the earliest in each patient, with regular assessment for DVT. Also, special 
attention towards the elderly is warranted with periodic ultrasound surveillance for the presence of 
DVT. 
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LIMITATIONS	  
 
This study was done as a prospective cohort study in the Medical Intensive Care Unit over a 
period of 10 months (June 2013 to April 2014).   
The recruitment of patients was planned as a consecutive sampling. Due to practical 
constraints, there were small lapses, despite which, consecutive sampling was attempted to the best 
possible extent.  
The study protocol included three consecutive ultrasound screening scans on the days 1, 3 and 
7 from the time of admission into the MICU. Although, repeat screening ultrasound scans at regular 
intervals, may have been ideal till the time of discharge; due to practical feasibility constraints, this 
could not be done.  Although it was seen that nearly half of the DVTs had resolved over the 
subsequent 3 days, and three fourths over a week; details regarding the time to resolution in the 
remaining patients could not be ascertained due to the above constraints.  
This study was restricted to the patients belonging to any of the five medical units in the 
hospital. There were patients from other medical specialties (like hematology, rheumatology, 
gastroenterology, cardiology, nephrology, neurology, medical oncology and endocrinology) who had 
got admitted to the MICU. They had not been considered for inclusion into the study as per protocol. 
The prevalence of certain risk factors for the development of DVT, which include, malignancies, 
thrombophilias, autoimmune diseases, and endovascular procedures & devices,  may have been higher 
in those patients from the afore mentioned specialties, especially hematology, medical oncology and 
rheumatology. Exclusion of these patients creates a lacuna in our understanding of DVTs and the 
adequacy of thromboprophylaxis in this high risk group.  
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The management of the DVTs encountered in this study was done according to the discretion 
of the treating physician. As a result, follow-up formal Doppler scans to look for progression or 
resolution of DVTs were not uniformly done in all patients with DVT. Initiation of oral 
anticoagulation was done in 13.6% (n=3/22) of patients with incident DVT who were discharged alive. 
These patients had become symptomatic during the later part of their hospital stay and the formal 
Doppler screening had revealed occlusive thrombus with proximal extension, which prompted 
initiation of anticoagulation. The resolution of DVT in the remaining patients was presumed at 
discharge from the hospital. Although these patients had been monitored in the ward for clinical 
features suggestive of DVT or its proximal propagation, most of the DVTs detected in the MICU were 
asymptomatic, implying the need for periodic surveillance with Doppler ultrasound in these patients; 
which was not done.  
Although the duration of central venous catheters was known in all the patients, a repeat 
Doppler scan following the removal of central venous catheters in patients with catheter related DVT 
would have been ideal, which was not done due to practical difficulties and feasibility constraints . A 
follow up scan following the removal of catheter would have not only ascertained the resolution, but 
would have also been helpful in determining the time to resolution. Determination of the time to 
resolution would have been useful while approaching the management of catheter related DVTs, as 
persistence beyond this time, would necessitate initiation of anticoagulation.  
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MERITS	  
 
 Our study is one of the few prospective studies in the country to describe deep venous 
thrombosis. It is the first study in India, to describe the occurrence of DVT exclusively in the medical 
intensive care unit. It is also the first in India to study patients while on thromboprophylaxis (100% 
coverage). The need for assessment of DVT among a high risk group (critically ill hospitalized medical 
patients) in a standard protocolized environment (while on thromboprophylaxis) was the driving force 
behind this study.  
 A uniform protocol (Appendix 1) for thromboprophylaxis was followed by all doctors in the 
medical intensive care unit, as a result of which all the patients studied were on standard 
thromboprophylaxis (pharmacological/mechanical/both). Therefore, the results are applicable to 
patients on thromboprophylaxis.  
 Regular screening ultrasound scans done at strategic points during the first week of admission 
into the MICU (which had been earlier identified by studies to be the high risk period for developing 
DVT) helped to detect several asymptomatic DVTs. The day 1 scan helped to exclude the DVTs at 
admission thereby, helping us to calculate the exact incidence of DVT after arrival into the MICU. Day 
3 and day 7 scans were planned as studies had previously shown that the maximum incidence of DVT 
in the MICU was after 48 hrs of ICU stay and after a week. This was helpful as our study helped to 
delineate the timeframe for the development of DVTs and their course in the medical intensive care 
setting.  
 As our study was done exclusively among patients from a medical intensive care unit; this was 
a more homogenous population being studied, the results of which will be applicable to patients in 
other medical ICUs. As this study was done in a hospital where the intensive care units are well 
integrated with the medical wards, the follow up was complete.  
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CONCLUSION	  
 
 Venous thromboembolism is one of the most common preventable causes of death in hospitals. 
Early recognition and appropriate management of deep venous thrombosis helps to save human lives 
and hospital resources. The risks for development of the same have been found to be similar across the 
world. Although, this entity was initially described among surgical patients, recent studies have shown 
that the risks are similar among medical patients, but arising from interplay of factors different from 
those in the former. Studies have shown that despite thromboprophylaxis being the standard of care in 
intensive care settings, it is largely underutilized in India.  
Our study showed that the incidence of DVT among critically ill patients in the medical 
intensive care unit was 17.2% on standard thromboprophylaxis.  Hence , there needs to be a low 
threshold for suspicion of DVT among the patients admitted to the medical intensive care unit.  
The incidence of non catheter related DVT was 5.9%. Only 13.6% of those with DVTs who 
were discharged, required to be started on oral anticoagulation therapy. Majority of the DVTs, 
especially the catheter related ones, had a favourable course. This could be attributed to meticulous 
thromboprophylaxis and timely removal of central venous catheters. Although, a large number of 
DVTs acquired in the medical intensive care unit, tend to resolve spontaneously and hence, have no 
effect on mortality, they seemed to increase morbidity. This was reflected by the observation that the 
presence of DVT appeared to increase the median duration of hospital stay by 10 days, thereby 
draining the financial and health care resources.  
The presence of central venous catheters seemed to independently influence the development of 
DVT in the medical intensive care setting. This risk was higher in the older patients. Hence, periodic 
Doppler surveillance and appropriate use of central venous catheters and their timely removal would 
be helpful in the management of the DVTs in the medical intensive care unit.  
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Appendix	  2	  –	  PROTOCOL	  FOR	  THROMBOPROPHYLAXIS	  
	  
All patients admitted in MICU/MHDU, are to be considered for thromboprophylaxis from day 
of admission into ICU/HDU. (50,56) 
Guidelines to be followed:  
 All patients are to be on unfractionated heparin by default, unless contraindicated, at a 
dose of  Inj. Heparin 5000U S/C BD 
 As an alternative, the patients may also be started on one of the following, instead of 
unfractionated heparin, depending upon the physician’s choice 
  Inj. Dalteparin 5000U S/C OD (or) 
  Inj. Enoxaparin (Clexane) 60mg S/C OD (or) 
  Inj. Fondaparinaux 2.5mg S/C OD 
 In the case of the following situations where anticoagulation is not advisable, the 
patient is to be on TED stockings. 
  Severe thrombocytopenia (<50000) 
  Deranged bleeding parameters (INR>1.5 or APTT >6s over the control) 
  Active bleeding (from any site) or active gastroduodenal ulcer 
  Recent stroke or History of bleeding in the past 3 mths 
  Hypersensitivity to any of the above drugs 
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Appendix	  3	  –	  DEFINITIONS	  
	  
Outcomes: 
DVT:  
Patients with any one or both of the following features on a screening 
ultrasound on D1/D3/D7 at any site and at one or more sites examined: 
Lack of compressibility on ultrasound 
Visualization of thrombus 
Death:  
a. ICU death: Mortality during the first seven days of admission to 
MICU/MHDU. (all causes / pulmonary embolism / sudden death) 
b. Hospital death: Mortality before discharge of the patient from the 
hospital. (all causes / pulmonary embolism / sudden death) 
 
Pulmonary embolism:  
 A PE was categorized as definite when confirmed by pulmonary angiogram, 
computed tomographic scan, magnetic resonance image, or pathologic examination of 
thrombus removed at surgery or autopsy(21) (or) in a patient with ECG (sinus 
tachycardia/S1Q3T3/T inversion in V1-V4) findings  plus ECHO (RA/RV 
dilatation/RV hypokinesia) findings suggestive of pulmonary embolism with high 
clinical probability of pulmonary embolism.(10) 
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Sudden death:  
Death in an otherwise hemodynamically and neurophysiologically stable 
patient, for which cause could not be attributed at the time of death. 
Discharge:  
Patients who have been discharged from hospital within completion of a week 
from the time of admission into the ICU/HDU and therefore the remaining data to be 
collected in those patients will be considered as missing data for all practical purposes. 
 
Exposures: 
Past history of 
  Surgery(43) – Recent surgery within the past 4 weeks, lasting for >1hr,  
     requiring atleast 3 days of post op hospitalization 
      Major abdominal surgery 
      Major orthopaedic surgery 
      Neurosurgery 
      Surgery for polytrauma  
  Trauma(43) – Recent major trauma within the past 4 weeks,  
    Major trauma – fracture / crush injury 
    Especially involving the extremities,  
124	  
	  
requiring atleast 3 days of hospitalization as part of its treatment 
  Previous DVT/Pulmonary embolism(43) – previous diagnosis of a  
pulmonary embolus or deep venous thrombus,  
based on objective methods (imaging) 
irrespective of the time of diagnosis 
DVT was categorized as definite when confirmed by venogram, 
computed tomographic scan, magnetic resonance image, or pathologic 
examination of thrombus removed at surgery or autopsy. A PE was 
categorized as definite when confirmed by pulmonary angiogram, 
computed tomographic scan, magnetic resonance image, or pathologic 
examination of thrombus removed at surgery or autopsy.(21) 
  Intake of OCPs/HRT(57,58) – for more than 3 months  
(concurrently at the time of admission or 
discontinued for not more than 1 week prior to 
admission)  
  Hospitalization(59) – for more than 2 days (for any reason) 
  Congestive Cardiac Failure(60) – Left Ventricular systolic dysfunction –  
    Presence of both clinical features suggestive of cardiac failure  
    (orthopnea, bibasal crepitations, NYHA-Class III-IV (61)) plus 
    Ejection fraction of =< 45% on ECHO   
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  Permanent pacemaker inserted (62) 
  Chronic Kidney Disease(63) – patients requiring dialysis or  
       Those diagnosed with nephritic syndrome 
  Chronic Liver Disease(64) – patients with clinical features and  
imaging suggestive of liver cirrhosis during 
the study or prior to it. 
  COPD(65) - Spirometric  evidence as  suggested by GOLD criteria.  
    FeV1/FVC<70% and  
post bronchodilator FeV1<805 of the predicted value 
Clinical and radiological features will be taken in to account in 
case of non availability of spirometry. 
  Malignancy - Patients with any of these malignancies  
including breast, colorectal and lung, cancers of the pancreas,  
ovary and brain or on anti neoplastic drugs for the same(66). 
(Active malignancy (or) currently on chemotherapy or palliation  
For the same or (or) completed treatment  
in the past 6 mths.)(43) 
Varicose Veins - All patients with varicose veins according to  
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international classification of diseases code: 183.9  
  Hypertension(12) – Blood pressure of > 140/90 as an  
average of 2 or more seated readings during  
each of 2 or more out patient visits 
  Diabetes Mellitus(12) –  
Clinical features of diabetes plus random plasma  
glucose levels > 200mg% (or)  
Fasting plasma glucose levels > 126mg% (or)  
2hrs after oral glucose tolerance test,  
plasma glucose levels > 200mg% (or)  
HbA1C levels > 6.5% 
  Thrombophilias(12) – congenital or acquired states of hypercoagulability 
 
 Predictors: 
  Age  
  Sex  
  Body Mass Index  
  Duration of hospital stay 
127	  
	  
  Duration of ICU stay 
  Mechanical ventilation 
  Central venous catheters / Peripherally inserted central catheters 
  Use of sedatives/muscle relaxants/vasopressors 
  Dialysis 
  Transfusions 
 Effect Modifiers: (with respect to thromboprophylaxis) 
  Smoking & Alcohol - Patients satisfying DSM IV TR criteria for  
alcohol and nicotine dependence syndrome. 
  Antiplatelets – Intake during the previous 1 week or concurrently(50) 
  Vitamin K supplements during the previous 1 week or concurrently(50) 
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Appendix	  4	  –	  DATA	  ABSTRACTION	  FORM	  (CLINICAL	  RESEARCH	  FORM)	  
	  
	  
	  
DRIVE STUDY – DETERMINATION OF INCIDENCE AND RISK FACTORS OF 
DEEP VENOUS THROMBOSIS IN THE MEDICAL INTENSIVE CARE UNIT 
DATA ABSTRACTION FORM 
Name:       Age:   Sex: Male / Female  
Address:                                                                                             Weight(estim): 
Contact number:                    Height: 
PRIMARY ADMISSION    /     RE-ADMISSION 
Admission source:  Same hospital ED / Same hospital ward / Inter-hospital 
Date of hospital admission:    Admission diagnosis:  
Date of ICU admission:     
Discharge date:                                                          Discharge diagnosis: 
 
Risk factors/Co-morbidities: (Circle features present at admission) 
Past History Present History 
Surgery/Trauma(<4weeks) Pacemaker Insertion Malignancy 
Hospitalization>3days Congestive cardiac Failure Hypercoagulable states 
Previous DVT/ 
Pul.embolism 
Chronic liver failure Pregnancy/Post partum 
Central lines / Dialysis ports  Chronic renal failure Immobilization 
(stroke/paresis) 
OCP intake(<4weeks)/HRT Smoking Alcohol intake 
NSAIDs use Aspirin/Clopidogrel Vit K supplements 
Rheumatic/autoimmune d/s   
Other Drugs(list)  
Serial No: Hosp. No: 
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Others (list)  
 
 SOFA Scoring at presentation =  
Local features:  erythema / warmth / swelling / tenderness / none 
Treatment details  
 Site/Comments From(date) To(date) Duration 
Central venous lines     
Peripherally inserted central 
lines 
    
Dialysis Ports     
Mechanical Ventilation     
Sedatives     
Muscle Relaxants     
Vaopressors     
Transfusions     
 
SOFA 0 1 2 3 4 
Respiratory 
P/F 
> 400 < 400 < 300 < 200 < 100 
Platelets > 150 < 150 < 100 < 50 < 20 
Vasoactive Nil MAP < 70 Dopa < 5 Dopa > 5 or Adr/NA 
<0.1 
Dopa >15 or Adr/Na 
>0.1 
GCS 15 13-14 10-12 6-9 < 6 
Bilirubin < 1.2 1.2 – 1.9 2.0 - 5.9 6.0 -11.9 > 12 
Renal < 1.2 1.2 – 1.9 2.0 – 3.4 3.5-4.9 or UOP < 500 
ml 
> 5.0 or UOP < 200 
ml 
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Diagnosis: 
SITES DAY # 1 
----/----/---- 
DAY # 3 
----/----/---- 
DAY # 7 
----/----/---- 
Right jugular    
Left jugular    
Right axillary    
Left axillary    
Right femoral    
Left femoral    
Right Popliteal    
Left Popliteal    
 
 
C- Vein compressible 
N-Vein not compressible 
P-Vein partially compressible 
NV-Vein not visualized 
T-Thrombus visualized 
 
Most recent value on /before D1 ___/___/___ D3 ___/___/___ D7 ___/___/___ 
PT/INR    
APTT    
platelets    
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Thromboprophylaxis: 
 
 None / Pharmacological / Mechanical(TEDS) / Both 
 
 If Pharmacological à LMWH / UFH / Fondaparinaux 
 
 If LMWH à Enoxaparin / Dalteparin 
 
 Dosage:  
 
Outcome: 
DVT Present:  yes / no 
D1 DVT:  yes / no 
Day of development of DVT:  
 From the day of hospital admission: 
 From the day of ICU/HDU admission: 
Site of DVT : jugular / axillary / femoral / popliteal 
Side of DVT: right / left 
 
Duration of ICU stay (days):  
Duration of hospital stay (days): 
ICU outcome:  Dead / Alive / Discharged at request/ PVS 
Hospital outcome:  Dead / Alive / Discharged at request / PVS 
Probable cause (s) of death: sudden death / confirmed pulmonary embolism / other causes 
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Appendix	  5	  –	  INFORMED	  CONSENT	  FORM	  
 
I.Information sheet 
Introduction: I($) am a post graduate student under the department of general medicine, 
doing research on deep venous thrombosis in critically ill patients admitted in medical 
intensive care unit & high dependency unit. I assure you(#) that every small detail regarding 
your participation in this study will be explained patiently to you in your own regional 
language; and consent may be given only if you are fully convinced of your role in the study . 
Purpose of the research: A “thrombus” is a clot in the blood vessel which usually occurs due 
to three factors – alterations in flow of blood, increased tendency of the blood to clot, and 
injury to the blood vessel wall. Deep venous thrombus refers to a clot in the deep veins of the 
body. It is of concern because it can lead to pulmonary embolism(clot in the pulmonary 
vessels) and inturn death,  if not identified and treated.  Deep venous thrombosis is a common 
problem in hospitalized patients, especially in patients of intensive care units, for which 
reason, there is already a pre-existing guidelines for preventing deep venous thrombosis are in 
place. Numerous studies pointing towards the occurrence of deep venous thrombosis in 
intensive care units despite measures to prevent the same, and limited studies on deep venous 
thrombosis in an Indian demographic, led us thinking on the lines of this topic, which 
necessitated a detailed evaluation and therefore shaping into this research paper. 
Participant selection: You are being requested to participate/allow your relative to participate 
in this study as you/he/she have/has been admitted in the *MICU/MHDU. The expected 
duration of the requested participation in this study would be 7 days from the time of 
admission into the intensive care unit , i.e., from the time of entering the study.  
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Voluntary participation: Your participation in this research is entirely voluntary. It is your 
choice whether to participate or not. Whether you choose to participate or not, the management 
and standard of care will remain the same. If you choose not to participate in this research 
project, you will still continue to receive the same standards of treatment.  You may change 
your mind later and stop participating even if you agreed earlier. 
Information on the research-Procedures & Protocol : All patients admitted in the *MICU 
& MHDU will be started on measures which prevent clot formation in blood, from the day of 
admission as per the routine standard guidelines (already being implemented here). Ultrasound 
screening for **DVT is one of the bedside investigatory tools that is used frequently in 
*MICU/MHDU to pick up **DVT in patients with a high degree of clinical suspicion, as it is 
often seen in this setting. In this study, every patient will be screened by self (or a 
coinvestigator) by ultrasound for **DVT in a methodical  manner, through three sequential 
scans over a period of one week. In addition, information regarding the patient’s past history, 
current clinical presentation, treatment details, course in *MICU/MHDU and outcome will be 
collected purely for research purposes. In the event of the patient being positive for **DVT 
during one of the tests, the relatives and the concerned unit will be informed and treatment for 
the same will be commenced immediately after discussion with the parent unit and the 
relatives. This study will have no bearing on the outcome of the patient. 
Appropriate Alternate Procedures: Bedside Compression ultrasound is an extremely safe, 
non invasive diagnostic tool used routinely for diagnosis of **DVT in *MICU/MHDU. 
Alternative procedures for **DVT include invasive procedures like venogram and more time 
consuming procedures like whole leg duplex ultrasonography. 
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Risks: This study has no risks; however the inherent risks arising from 
hospitalization,*MICU/MHDU stay, **DVT or its sequele will exist independent of the study. 
Benefits: This study tries to elevate the standards of care already being offered to patients by 
offering more efficient ways than routine, of diagnosing **DVT by frequent ultrasound scans, 
and thereby starting early diagnosis and treatment of the same to prevent its sequele. 
Reimbursements: You will not be charged the cost of the sequential ultrasound scans which 
are done as a part of the study. There are no other incentives. The patient will not be paid for 
his/her  participation  in the study. 
Confidentiality: Your name will not be mentioned anywhere neither the data sheet nor the 
final published study. Your data will bear a study number and the number will be used till 
analysis.  
Sharing of the result:  The result of this research is a property of Christian Medical College, 
Vellore; and I am entitled to publish it in a journal or present it in a conference. The participant 
will have no claim towards the same. 
Right to Refuse or Withdraw: You do not have to take part in this research if you do not 
wish to do so. You may also withdraw participating in the research after giving the consent. It 
is your choice and all of your rights will be respected. 
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II.Certificate of Consent 
Study Title: Detrmination of Incidence and Risk Factors For Deep Venous Thrombosis in the 
Medical Intensive Care Unit 
Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please tick the boxes: 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I 
understand that my identity will not be revealed in any information released to third parties or 
published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
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Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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Appendix	  6	  –	  GLOSSARY	  
	  
DVT – Deep Vein Thrombosis 
VTE – Venous Thromboembolism 
PE – Pulmonary Embolism 
MICU – Medical Intensive Care Unit 
ICU – Intensive Care Unit 
MHDU – Medical High Dependency Unit 
HDU – High Dependency Unit 
CMC – Christian Medical College 
SD – Standard Deviation 
IQR – Inter quartile Range 
PT – Prothrombin Time 
INR – International Normalized Ratio 
APTT – Activated Partial Thromboplastin Time 
DAMA – Discharge Against Medical Advice 
SOFA – Sequential Organ Failure Assessment score 
SPSS – Statistical Package for Social Sciences 
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